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include additional analysis of the submitted evidence or new clinical and/or 
economic evidence.  
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1 Summary 
Scope of the Company’s submission  
The Company’s submission is relevant to the decision problem defined in the 
Scope. 
Summary of clinical evidence submitted by the Company 
The Company has provided evidence on the longevity of ENDURALIFE-
powered CRT-Ds compared to comparator CRT-Ds in the form of six case 
series studies (referred to by first author: Alam, Ellis, Landolina, Lau, von 
Gunten, Williams) [1-7], four of which are published in full (Alam, Ellis, 
Landolina, von Gunten) [1-4;6] and two of which are available as abstracts 
[5;7]. One of the case series studies is reported in two papers, the second 
with longer follow-up [1;2]. All analyses are retrospective. The studies show 
that for devices implanted during the time interval c2008-c2010, 
ENDURALIFE-powered CRT-Ds have better longevity than their 
contemporarily implanted comparator CRT-Ds. In the Landolina study [4] the 
number of CRT-Ds still in service at five years following implantation were 
88% for Boston Scientific, 75% for St Jude Medical and 52% for Medtronic. In 
the company’s economic model CRT-D longevity data were used as inputs 
based on a subsequent, accepted-for-publication economic analysis by the 
same group of authors and based broadly on the same patient series 
(Landolina 2016, unpublished). For ENDURALIFE-powered CRT-Ds 
implanted during this period, the advantage in longevity represents a longer 
interval until a replacement procedure is required. The Company’s submission 
includes Product Performance Reports (PPRs) which, for this evaluation 
serve only to demonstrate that it is normal battery depletion, rather than CRT-
D malfunction, that is the main reason that a CRT-D device needs to be 
replaced. The evidence on rates of complications associated with CRT-D 
replacement procedures is fairly clear: a large, Danish cohort study reports 
that replacement procedures carry a 5.9% risk of any complication and a 
3.5% risk of major complications.  
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Summary critique of clinical evidence submitted by the Company  
The evidence for the comparative longevity of CRT-Ds, based on four 
retrospective case series published in peer reviewed journal papers (plus two 
abstracted reports), is acceptably robust. Three of the studies include over 
1000 participants. A minor limitation is that analyses are observational and 
retrospective. The five submitted Product Performance Reports depend upon 
explanted devices being returned to companies for analysis, or companies 
otherwise determining their status by active tracking. Production of Product 
Performance Reports is prone to differences in specifications across 
manufacturers and some reports have been shown to over-estimate CRT-D 
longevity compared to published clinical research studies. The clinical 
evidence on rates of complications associated with replacement of CRT-Ds is 
based on replacement of a broader group of cardiac implantable electrical 
devices, but has acceptable applicability to replacement of CRT-Ds. The best 
available data on complications associated with replacement procedures is 
based on a large Danish cohort study. 
Summary of economic evidence submitted by the Company 
The Company submitted 7 economic studies and a de novo model. They 
relied on the de novo model to support their claimed benefits and used the 
published and unpublished economic studies to demonstrate consistency with 
the published literature. 
Summary critique of economic evidence submitted by the Company  
The EAC excluded 3 of the economic studies as outside of the scope.  
In the model the company relied upon the same average selling price data 
from TA314 for each of the technologies, which is not fit for purpose in this 
single medical technology evaluation where we need to see price data from 
each manufacturer for their technologies.  
The company relied in the model on applying Boston Scientific’s warranty 
arrangements to the comparator technologies.  
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There was an attempt by the company to update longevity data to reflect 
improvements in longevity of current technologies, but this assumed that the 
device survival profile across each manufacturer was unchanged since 2008-
10. 
The 6 year time horizon of the model was chosen because of available follow-
up in the clinical studies. A better time horizon would be based on patient life 
expectancy to demonstrate whether differences in device replacement rates 
are significant in relation to life expectancy. 
External Assessment Centre commentary on the robustness of evidence 
submitted by the Company 
The clinical evidence submitted by the company is acceptably robust and 
reflects the performance of ENDURALIFE-powered CRT-Ds implanted in the 
period c2008-c2010, showing their superiority at that time in terms of CRT-D 
longevity. The nature of undertaking empirical research in real life clinical 
settings is that lengthy follow-up is needed to see useful longevity data: only 
recently have the relevant peer reviewed results been published, and these 
form the basis of the Company’s submission. A procurement professional 
today would observe that newer and different CRT-D models are supplied 
today, compared to the models in the published studies described above. The 
EAC considers that there have likely been numerous innovations across 
different manufacturers since the time when these studies were initiated. Such 
innovations are unlikely to be limited to the battery alone, but to other 
components of the device (e.g. capacitor, microprocessor) and to how it 
interacts with the heart. These are discussed in detail in the technical 
assessment. The EAC considers that the empirical evidence in the 
Company’s submission is robust, but it is uncertain whether it has direct 
applicability to CRT-Ds marketed today. Whether differences in longevity 
between ENDURALIFE-powered CRT-Ds and comparators lead to a 
reduction in replacement procedures depends on patient life expectancy. 
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Summary of any additional work carried out by the External Assessment 
Centre 
The EAC searched for and did not identify any further studies of head-to-head 
comparisons of CRT-D longevity across manufacturers. Based on expert 
clinical advice, the EAC has included a Danish cohort study providing data on 
rates of complications associated with replacement procedures.  
The EAC obtained list prices for the technology and the comparators and re-
ran the model using these inputs for device cost. The EAC also did a 
threshold analysis using the average selling price for the ENDURALIFE 
powered CRT-Ds and allowing the comparator purchase cost to fall to the 
point at which each becomes cost neutral. 
The EAC obtained warranty data from the comparator manufacturers and 
substituted this into the formulae in the model. 
The EAC substituted NHS reference costs where the company had used PbR 
tariff costs in the model. 
Based on information from clinical advisers the EAC modified the sensitivity 
analysis for complication rates (infection) based on the results of a large 
Danish cohort study. 
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2 Background  
2.1 Overview and critique of Company’s description of clinical 
context 
The Company presents a thorough description of the clinical context for 
ENDURALIFE powered CRT-D devices. The population is described as per 
the Scope i.e. people with heart failure and a left ventricular ejection fraction 
(LVEF) <35%, classified according to New York Heart Association (NYHA) 
functional classification system, presence/absence of left bundle branch block 
(LBBB) and QRS interval observed on electrocardiogram (ECG). Higher 
NYHA class (range I-IV) represents more life-limiting heart failure. The 
Company’s description of clinical context makes reference to, and is 
consistent with NICE TA314 and NICE CG108. 
CRT-Ds are one type of a number of implantable devices that may be 
indicated in the NICE care pathway. All implantable devices are selected after 
medical therapies have been attempted.  
The Company cites evidence suggesting that the number of patients receiving 
de novo CRT-Ds is growing and also the number of patients undergoing 
replacement CRT-D procedures.  
The Company’s submission is appropriate and relevant to the decision 
problem under consideration. The Company’s main claimed benefit is that 
ENDURALIFE-powered CRT-D devices would require less frequent 
replacement than comparator CRT-D devices. For patients this would bring a 
benefit through less frequent invasive surgery and its risk of complications. A 
system benefit would result from releasing a quantity of cardiac 
catheterisation clinic time for other procedures. There are no other significant 
changes in care pathway arising through the use of ENDURALIFE-powered 
CRT-Ds. 
2.2 Overview of Company’s description of ongoing studies 
The Company identifies two ongoing studies of ENDURALIFE-powered CRT-
D devices. 
The Company reports that it is conducting a prospective, non-comparative 
single arm observational cohort study (n = 1600) to assess the rate and cause 
of device replacements for Boston Scientific ICDs and CRT-Ds at 5 years 
post-implantation (anticipated publication May 2021). Although relevant to the 
scope, this study will not be ready for publication within the guidance 
development timeframe. 
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The company also makes reference to the UK British Heart Rhythm 
Society/NICOR Cardiac Rhythm Management National Clinical Audit registry 
focusing on device longevity. 
In addition the EAC identified three additional ongoing studies, none of which 
are directly relevant to the decision problem. These are shown for reference in 
Appendix 1 and do not otherwise contribute to this report. 
2.3 Critique of Company’s definition of the decision problem 
Population 
With regard to population, the clinical evidence submitted by the Company 
has a high degree of applicability to the Scope. All cited studies are of people 
with heart failure and the included longevity studies present the cardiac 
morbidity of the study participants, indicating that they represent the 
population specified in the scope. 
Intervention 
The intervention studied in the clinical evidence submitted by the Company 
fits the scope. Although some longevity studies study ICDs as a wider group 
of devices, rather than only CRT-Ds, they present adequate data on the CRT-
D subgroup to enable comparisons of CRT-D devices across manufacturers. 
EAC Description of a CRT-D device 
A CRT-D device is an implantable medical device used to increase cardiac 
output in selected patients with heart failure, and also to correct occasional, 
life threatening arrhythmias. 
Implantation of a CRT-D device is usually done in a cardiac catheterisation 
lab under local anaesthetic. The heart is visualised using fluoroscopy to 
provide a continuous image on a screen. A catheter is introduced to a vein 
beneath the collar bone then the leads are introduced through the catheter 
until the lead tips are correctly placed in the right atrium, right ventricle and 
external to the left ventricle via the coronary sinus vein (see technical 
assessment). An incision is made in the skin beneath the collar bone to create 
a pocket underneath the subcutaneous fat. The generator is connected to the 
leads and is placed in the pocket before the incision is closed. 
Once functioning, the CRT-D device continuously monitors the electrical 
activity of the heart and in response provides cardiac resynchronisation 
therapy, meaning that it provides electrical pulses to ensure that the two 
ventricles contract together in a coordinated fashion. This places a frequent, 
but relatively small demand for power on the battery. When the device detects 
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a dangerous arrhythmia (ventricular tachycardia or ventricular fibrillation) the 
CRT-D delivers a cardioversion ‘shock’ to the heart to restore normal sinus 
rhythm. This occurs less frequently in most patients but places a large 
demand for battery power. In addition shocks may be distressing for patients, 
so careful counselling is provided when CRT-D is considered as a therapy for 
heart failure. 
ENDURALIFE-powered CRT-D devices 
The company’s submission states that the following Boston Scientific CRT-D 
devices are powered by the ENDURALIFE battery technology: 
COGNIS™ CRT-D Family 
ENERGEN™ CRT-D Family 
PUNCTUA™ and PUNCTUA™ NE CRT-D Family 
INCEPTA™ CRT-D Family 
AUTOGEN™ CRT-D Family 
INOGEN™ CRT-D Family 
DYNAGEN™ CRT-D Family 
ORIGEN™ CRT-D Family 
Regulatory approval  
All of the above devices may be marketed in the European Union. For CE 
marking purposes the COGNIS device has Design-Examination Certificate no. 
CE531475 for conformity with EC Council Directive 90/385/EEC Annex 2 
Section 4. For the INCEPTA, ENERGEN, PUNCTUA NE and PUNCTUA 
CRT-Ds the Design-Examination Certificate no. is CE566332 and for the 
AUTOGEN, DYNAGEN, ORIGEN and INOGEN CRT-Ds the Design-
Examination Certificate no. is CE602838. 
These CRT-D devices are often referred to as ‘the generator’, and the 
generator is implanted with three leads which conduct electrical energy from 
the generator to the heart muscle. The leads are separate medical devices 
requiring their own regulatory approval. 
Comparator(s) 
The comparators are CRT-D devices that are not powered by the 
ENDURALIFE battery technology. In terms of evidence, this is represented 
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broadly by head-to-head comparisons of CRT-Ds from different 
manufacturers, of which, based on marketing information and published 
studies there are four: 
 St Jude Medical 
 Medtronic 
 Biotronik 
 Sorin (now Liva Nova) 
All of the studies provide as comparator, CRT-Ds from the above companies. 
Some studies include other types of cardiac implantable electrical devices 
(CIEDs) in addition to CRT-Ds. 
Outcomes  
The six submitted studies of longevity report the following outcome measures: 
 Rate of replacement due to battery depletion (device reaching ERI) 
 Time to battery depletion (ERI) 
 % battery survival at successive years’ follow-up 
 Reasons for devices being out of service (mortality, heart 
transplantation, device revision/replacement (including due to 
infection), device or lead failure) 
 Factors associated with device longevity 
In addition the studies report CRT-D operating parameters which are either a 
‘fixed quantity’ for that device, or that are a result of interaction between the 
device, the leads and the patient. These are reported because they may 
influence the rate of battery discharge and hence battery life and hence 
device longevity. These factors are addressed in the EAC’s Technical 
Assessment. 
PPR data suggest that the biggest driver of device longevity is normal battery 
depletion, rather than device malfunction. 
Cost analysis 
The cost analysis in the Company’s submission matches the cost analysis 
specified in the final scope. 
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Subgroups 
No subgroups are specified in the Scope or reported in the Company’s 
submission. Some studies present data on a subgroup CRT-Ds considered to 
be newer generation devices at the time of publication: this reflects the timing 
of the study recruitment periods and it is generally the case that the ‘newer 
generation’ subgroup broadly contains the ENDURALIFE-powered CRT-Ds. 
Special considerations, including issues related to equality 
The published studies suggest that people who undergo implantation with 
CRT-D devices are, on average, elderly and predominantly male. The EAC 
does not anticipate that this is indicative of inequity of access to treatment, but 
expects that the study samples reflect the epidemiology of heart failure. 
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3 Clinical evidence 
3.1 Critique of the Company’s search strategy 
The Company conducted two searches for published literature on: 
• studies of device longevity 
• the incidence of complications associated with device replacement and 
outcomes relating to patient quality of life or satisfaction associated 
with device replacement. 
For the search of studies of device longevity the Company did not search all 
the databases that are recommended in the Company template, no 
explanation was provided. The Company searched the following databases 
and sources: PubMed; Cochrane; ClinicalTrial.gov and libraries held by the 
Company. 
The strategies used for the searches of PubMed and Cochrane were 
assessed in accordance with the PRESS checklist (Peer Review of Electronic 
Search Strategies). The strategies used were simplistic, did not incorporate 
subject headings and did not contain a broad selection of terms or reflect the 
intervention described in the PICO. The Company limited the search to 
studies published from 2008 which is in keeping with the first commercial 
launch of the technology.  
The search of ClinicalTrial.gov is appropriate to identify ‘Ongoing and 
Completed’ trials but would only identify studies that are registered as a 
clinical trial. From searches conducted by the EAC we believe that the only 
relevant ongoing trial has been identified. 
The Company’s library is likely to be a good repository of studies for this 
technology and probably contains all the relevant studies. The Company also 
collected abstracts, congress publications and other external communications 
but no details were provided as to how this was done. 
For the clinical evidence there were a limited number of records identified 
which reflects the simplicity of the search. The Company conducted a 
separate search for outcomes related to device replacement which retrieved 
significantly more records. This search was simplistic and likely to overlap 
with the search for clinical evidence. The two searches could have been 
incorporated into one search. 
A further search method that the Company could have conducted to ensure 
that all relevant studies had been identified would have been to citation track 
the selected included publications. 
The Company included adverse events that were reported in the MAUDE 
database but no details were provided on the search. It should be noted that 
Medical Device Reports (MDRs) within the MAUDE database are collated as 
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a result of a passive surveillance system that has limitations such as the 
potential submission of incomplete, inaccurate, untimely, unverified or biased 
data. 
However despite some inadequacies of the search methods we believe that 
the Company has identified all the relevant literature for this technology at the 
time of writing their report.  
3.2 Critique of the Company’s study selection 
The Company presents a flow diagram of study selection (as per PRISMA 
statement) and has selected appropriate studies reporting longevity of 
ENDURALIFE-powered CRT-D devices compared to comparator devices 
implanted in a contemporary period.  
Study selection criteria were consistent with the Scope, for example the 
Company took the reasonable step of excluding studies where ENDURALIFE-
powered CRT-Ds comprised less than 50% of devices studied. Inclusion of 
the von Gunten study is an exception, since in this study only 39% of Boston 
Scientific CRT-Ds are powered by the ENDURALIFE battery technology. 
However a supplement to this paper reports longevity for 76 ENDURALIFE-
powered COGNIS CRT-Ds. The remainder of the studies of CRT-D longevity 
include participants who underwent implantation from 2008 onwards i.e. the 
point from which ENDURALIFE battery technology became available, 
whereas the von Gunten study [6], included people implanted between 1994 
and 2014. 
3.3 Included and excluded studies 
The Company’s submission of clinical evidence comprises three main 
categories of clinical evidence: published studies reporting longevity, Product 
Performance Reviews (PPRs) produced by manufacturers and studies 
reporting complication rates following replacement of CIEDs. 
Published studies comparing CRT-D longevity across manufacturers 
The company includes six case series studies of CRT-D device longevity 
reported in seven sources [1-7]: four studies are published in full as journal 
articles [1-4;6]. Of these, one study is reported in two papers at different 
follow-up points [1;2] Two studies are reported only as conference abstracts 
[5;7]. All analyses are retrospective. For ease of reference we will refer to 
these studies by their first author’s names as follows: 
 Alam [1;2] 
 Ellis [3] 
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 Landolina [4] 
 Lau [5] 
 von Gunten [6] 
 Williams [7] 
Table 1 presents an overview of the key features of these studies. 
Product Performance Reviews 
The five PPRs were produced by the five manufacturers of CRT-D devices. 
Production of PPRs is recommended by the US Heart Rhythm Society Task 
Force and has been taken up by all manufacturers of CRT-D devices. PPRs 
aim to report device malfunctions in a standard format and are based only on 
data derived from explanted devices returned to the manufacturer. Return 
rates are acknowledged to be less than 100%. 
Published studies reporting complications due to replacement 
procedures 
The manufacturer’s submission contained 19 studies that highlight the 
complications associated with ICD and CRT-D replacement; these were not 
device or manufacturer specific. These are references 29-47 in the 
Company’s submission of evidence. Only one of these studies was used by 
the company to provide inputs to the economic model [8]. 
The EAC sought advice from clinical experts which identified a Danish Cohort 
study [9] as the best source of evidence on complications following de novo 
and replacement implant procedures. 
Patient preference 
One additional submitted study investigated the patient’s perspective on 
device size compared to device longevity [10]. 
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Table 1. Characteristics of 7 published observational studies reporting battery survival 
Study & 
country 
Patient 
population  
CRT-D devices studied Study design Sample size EAC comments 
Alam 2016 
USA 
Full journal 
article 
 
Patients implanted 
with CRT-D 
between 1 Jan 
2008 and 31 Dec 
2010: (last access 
to patient record 
20 Dec 2015): 
Boston Scientific: 
173 
Medtronic: 391 
St Jude Medical: 
57 
Gender 
Male: 484/652 = 
74% 
Female: 168/652 = 
26% 
Age 
Mean 69 (SD 3) 
years 
Cardiac 
morbidity 
CHD 64% 
LVEV 29 (SD 12) 
% 
As per Alam 2014 below, but subject to additional loss to follow-up. Retrospective 
cohort, single 
centre 
(University of 
Pittsburgh 
Medical Center) 
reported as full 
journal article. 
This is an 
update of the 
same cohort 
reported by 
Alam et al. 
2014 cited 
below. 
Included 
Total n = 621 
Boston 
Scientific: 173 
(28%) 
Medtronic: 
391 (63%) 
St Jude 
Medical: 57 
(9%) 
Excluded 
Boston 
Scientific: 31 
Medtronic: 55 
St Jude 
Medical: 8 
Biotronik 6 
Exclusions 
were due to 
follow-up loss, 
change of 
follow-up 
provider or 
due to small 
numbers of 
Losses to follow up 
since the publication of 
Alam 2014 seem to be 
patients with Medtronic 
CRT-D devices (n = 
25). In the Boston 
Scientific group loss to 
follow up for 2014 (n = 
32) versus 2016 (n = 
31) must represent a 
minor error. Of 173 
Boston Scientific 
devices studied, 122 
were powered by the 
ENDURALIFE battery 
technology, so 
comparisons by 
manufacturer do not 
have complete 
applicability to the 
scope. 
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Study & 
country 
Patient 
population  
CRT-D devices studied Study design Sample size EAC comments 
Paced QRS width 
mean 155 (SD 29) 
ms 
implants 
(Biotronik). 
Alam 2014 
USA 
Full journal 
article 
(earlier 
report of 
same study 
as Alam 
2016, above) 
Patients implanted 
with CRT-D 
between 1 Jan 
2008 and 31 Dec  
2010 (last access 
to patient record 
15 Apr 2013): 
Boston Scientific: 
173 
Medtronic: 416 
St Jude Medical: 
57 
Gender 
Male: 484/652 = 
74% 
Female: 168/652 = 
26% 
Age 
Mean 69 (SD ±13) 
years 
Cardiac 
morbidity 
CHD 64% 
Boston Scientific: 
ENDURALIFE-powered CRT-Ds:  
N118 COGNIS 100-D (22) 
N119 COGNIS 100-D (100) 
Other: 51 
Medtronic: 
8042 InSync III: (6) 
C154DWK Concerto: (178) 
C154VWC Concerto (1) 
D224TRK Consulta (227) 
D274TRK Concerto II (1) 
D284TRK Maximo II (3) 
St Jude Medical: 
3207-30 (3) 
3207-36 (37) 
CD3211-36 (14) 
CD3215-36Q (1) 
3211-36 (1) 
3211-36Q (1) 
Retrospective 
cohort, single 
centre 
(University of 
Pittsburgh 
Medical Center) 
reported as full 
journal article. 
Included 
Total n = 646 
Boston 
Scientific: 173 
(27%) 
Medtronic: 
416 (63%) 
St Jude 
Medical: 57 
(9%) 
Excluded n = 
100: 
Boston 
Scientific: 32 
Medtronic: 55 
St Jude 
Medical: 7 
Biotronik 6 
Exclusions 
were due to 
follow-up loss, 
change of 
follow-up 
provider or 
due to small 
Full journal article. Of 
173 Boston Scientific 
devices studied, 122 
were powered by the 
ENDURALIFE battery 
technology, so 
comparisons by 
manufacturer do not 
have complete 
applicability to the 
scope. 
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Study & 
country 
Patient 
population  
CRT-D devices studied Study design Sample size EAC comments 
LVEV 29 (SD ±12) 
% 
Paced QRS width 
mean 155 (SD 
±29) ms 
numbers of 
implants 
(Biotronik). 
Ellis 2016 
USA 
1302 Patients 
(NYHA Class II-IV) 
implanted with 
CRT-D between 1 
Aug 2008 and 31 
Dec 2010 (last 
data entry 31 Dec 
2014): 
Gender 
Male: 73% 
(n=950/1302) 
Female: 27% 
(n=352/1302) 
Age 
Mean 68.1 (SD 
±11.8) years 
Cardiac 
morbidity 
Mean LVEF 25.1% 
(SD ±10.1%) 
Mean QRS 
duration 152.0 (SD 
Device names not reported. Retrospective 
multicentre 
study 
(Vanderbilt 
Heart and 
Vascular 
Institute) 
reported as full 
journal article. 
Total n = 1302 
BSC: n = 322 
(24.7%) 
MDT: n = 794 
(60.9%) 
SJM: n = 186 
(14.2%) 
Full journal article. 
Authors report that the 
proportion of devices by 
manufacturer 
represents the market 
share distribution. No 
exclusions are reported. 
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Study & 
country 
Patient 
population  
CRT-D devices studied Study design Sample size EAC comments 
±25.6) ms 
Reason for 
implantation: 
Ischaemic 
cardiomyopathy 
56.3% 
(n=731/1299)) 
Nonischaemic 
cardiomyopathy 
41.9% 
(n=544/1299) 
Type of 
implantation: 
De novo: n = 
496/1302 (38.1%) 
Replacement: n = 
480/1302 (36.9%) 
Revision: n = 
52/1302 (4.0%) 
Upgrade: n = 274 
(21.0%) 
Landolina 
2015 
Italy 
1726 patients with 
heart failure 
implanted with 
CRT-D devices 
between Jan 2008 
and Mar 2010 
(data accessed 
March 2014). 
Manufacturer Device Release Battery chemistry Capacity n 
Biotronik 
Lumax 300  2006 Li/MnO2  1.28Ah  3 
  
Li/CFx-SVO  1.72Ah 
 
Lumax 340  2006 Li/MnO2  1.28Ah  26 
  
Li/CFx-SVO  1.72Ah 
 
Lumax 540* 2008 Li/MnO2  1.72Ah  20 
  
Li/CFx-SVO  1.72Ah 
 
Retrospective 
cohort study of 
nine centres 
reported as full 
journal article. 
n = 1726 
CRT-D 
devices: 
Biotronic n = 
49 (3%) 
Boston 
Scientific n = 
Full journal article. Of 
608 patients in the 
Boston scientific group 
291 had the Cognis 
CRT-D i.e. 48% were 
powered by the 
ENDURALIFE battery 
technology. Paper does 
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Study & 
country 
Patient 
population  
CRT-D devices studied Study design Sample size EAC comments 
Gender/age not 
reported. 
Implantation 
type: 
De novo: n = 1071 
(62%) 
Replacement: n = 
472 (27%) 
Upgrade: n = 183 
(11%) 
Boston Scientific 
Renewal  2004 Li/SVO  2.00Ah  288 
Livian  2007 Li/CFx-SVO  1.86Ah  29 
Cognis* 2008 Li/MnO2  1.84Ah  291 
Medtronic 
InSync III Marquis  2003 Li/SVO  0.90Ah  67 
InSync Sentry  2004 Li/SVO  0.89Ah  7 
InSync Maximo  2005 Li/SVO  0.89Ah  21 
Concerto  2006 Li/SVO  1.00Ah  171 
Consulta* 2008 Li/SVO  1.00Ah  447 
Maximo II* 2008 Li/SVO  1.00Ah  69 
Protecta* 2010 Li/SVO  1.00Ah  16 
Sorin  
Ovatio  2005 Li/SVO  0.87Ah  30 
Paradym*  2008 Li/CFx-SVO  1.96Ah  69 
St Jude Medical,  
Atlas  2003 Li/SVO  b  40 
  
Li/SVO  b 
 
Epic  2006 Li/SVO  b  26 
Promote* 2007 Li/SVO  b  106 
  
Li/SVO  b 
  
* considered to be ‘new generation’ 
All devices were programmed to deliver true biventricular pacing. 
608 (35%) 
Medtronic n = 
798 (46%) 
Sorin n = 99 
(6%) 
St Jude 
Medical n = 
172 (10%) 
 
146 (8%) 
patients were 
censored 
since they 
chose to 
receive follow-
up at non-
study centres. 
not report patient 
demographic and 
cardiac disease data. 
Survival analysis 
(Kaplan-Meier & log-
rank test): Patients 
were censored at the 
time of death (n = 274) 
or the last outpatient 
follow-up visit: 146 
patients were censored 
due to receiving follow-
up in other centres.. In 
the analysis of the time 
to battery depletion, 
removals for other 
causes were not 
counted as events and 
patients were censored 
at the time of their 
occurrence. 
Although only 48% of 
BSC CRT-Ds were 
powered by the 
ENDURALIFE battery 
technology, the analysis 
of recent generation 
devices (marketed 2007 
onwards) appears to 
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Study & 
country 
Patient 
population  
CRT-D devices studied Study design Sample size EAC comments 
include COGNIS 
devices i.e., 100% 
ENDURALIFE-powered 
CRT-Ds. 
Lau 2015 
UK 
Patients with CRT-
Ds implanted in 
2008-9. 
 
 
Manufacturer 
Device Battery 
chemistry 
Total 
capacity 
(Ah) 
Usable 
capacity 
(Ah) 
Ratio 
Boston 
Scientific  
Cognis n=27  LiMnO2  2  1.8 0.9 
St Jude 
Medical  
Promote/Atlas HF 
n=66 
LiSVO  1.87  1.31 0.7 
Medtronic  Consulta/Concerto 
Maximo n=62 
LiSVO 1.4 1 0.7 
 
Single centre 
case series 
reported as a 
conference 
abstract. 
n = 321 
 
Study available as 
abstract only: many 
details not reported, 
including patient 
factors, number of 
subjects per group and 
average follow-up. 
Study is most likely 
retrospective (not 
reported). Non ERI 
events leading to 
removal of CRT-Ds 
from service were 
censored. 
von Gunten 
2015 
The 
Netherlands / 
Switzerland 
3436 Patients with 
heart failure of 
NYHA class I-IV 
fitted with 4881 
ICDs (VVI, DDD, 
CRT-D) at two 
centres between 
March 1994 and 
January 2014. 
Boston Scientific CRT-D devices studied (n = 259): 
Device   
Cognis CRT 76 1 
Contak CD 1823  11 4 
Contak Renewal 2 H155  30 16 
Contak Renewal 4 190  1 1 
Contak Renewal 4 AVT M177 HE  23 13 
Contak Renewal 4 H195 15 8 
Contak Renewal 4 HE H199  14 10 
Contak Renewal 4 RF H230 31 10 
Contak Renewal 4 RF H235 9 2 
Contak Renewal H135 21 15 
Energen CRT 24 0 
Energen DR 9 0 
Retrospective 
cohort study (2 
centres: 
Erasmus, 
Netherlands, 
Basel, 
Switzerland). 
3436 patients 
in total, of 
which: 
2154 were 
alive in the 
study as of 5 
June 2014 
822 died 
85 underwent 
transplant 
Full journal article. The 
paper reports on out-of 
scope implantable 
devices for the majority 
of participants (74%). 
The paper reports 
baseline characteristics 
(demographic, cardiac 
morbidity, NYHA class, 
medical therapies) for 
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Study & 
country 
Patient 
population  
CRT-D devices studied Study design Sample size EAC comments 
Data last 
accessed: 31 May 
2014 (Erasmus), 
30 June 2014 
(Basel). 
N (CRT-D devices) 
= 1284/ = 26% 
N (BSC CRT-D 
devices) = 
102/259 = 39%” 
Gender 
Male: 2721/3436 = 
79% 
Age 
Mean 59 (SD±14) 
years 
Cardiac 
morbidity 
Mean LVEF 32 % 
(SD±13%) 
Mean QRS 
duration 127 (SD 
±35) ms 
Ischaemic 
cardiomyopathy 
74% 
Energen VR 28 0 
Incepta F 162 2 0 
Incepta P 163 1 0 
Incepta P 165 1 0 
Teligen CRT 2 0 
Teligen DR 28 0 
Teligen VR 82 0 
Ventak Mini 4 1793 34 22 
Ventak Prizm 1850 4 4 
Ventak Prizm 2 1851 9 7 
Ventak Prizm 2 1860 35 26 
Ventak Prizm 2 1861 46 29 
Ventak Prizm AVT 1900 5 3 
Ventak Prizm HE 1852 28 23 
Ventak Prizm HE 1853 22 15 
Vitality 1871 65 38 
Vitality 2 EL 9 0 
Vitality 2 EL T177 48 10 
Vitality 2 T165 77 20 
Vitality 2 T175 142 21 
Vitality A 155 3 1 
Vitality VR 1870 12 12 
Of the above 141 shown in bold 102 are ENDURALIFE-powered CRT-D devices. 
154 were lost 
to follow-up 
32 were 
downgraded 
or not 
replaced. 
the entire cohort and 
not by analysis groups. 
Paper reports how 
many patients were 
censored due to 
competing risks (not 
reported by analysis 
group): 
822 died 
85 underwent heart 
transplant 
189 moved to other 
hospitals 
154 were lost to follow-
up. 
A supplement to this 
paper reports longevity 
for 76 ENDURALIFE-
powered COGNIS 
CRT-Ds at 4 years 
following implantation. 
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Study & 
country 
Patient 
population  
CRT-D devices studied Study design Sample size EAC comments 
Williams 
2014 
USA 
90 patients with 
CRT-Ds implanted 
between 1 July 
2008 and 31 July 
2010.  
Gender: not 
reported 
Age: mean 72 (SD 
±9) years 
Cardiac 
morbidity: 
Mean 
creatinine,1.3 (SD 
±0.5) mg/dl 
Mean ejection 
fraction 0.25 (SD 
±0.08) % 
Device names not reported. Retrospective 
cohort at a 
single 
nonacademic 
community 
hospital 
reported as a 
conference 
abstract. 
Total (n = 90) 
Boston 
Scientific 
(n = 53) 
Medtronic 
(n = 28) 
St Jude 
Medical 
(n = 10).  
Study available in 
abstract only: full details 
not reported, including 
values for some 
outcome data.  
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3.4 Overview of methodologies of all included studies 
Published studies comparing CRT-D longevity across manufacturers 
The EAC has critiqued the six studies of CRT-D longevity, considering these 
key evidence against which the company’s claimed benefits may be judged. 
For the studies published as full journal articles, critical appraisal checklists 
are included in Appendix 3. An overview of study characteristics is provided 
here and Table 3 shows the key features of each individual study of CRT-D 
longevity. 
Population 
The studies of longevity are retrospective analyses of case series originating 
from the USA, Europe and the UK. The patient samples studied have a 
majority of male participants (73-79% where reported) and average age at 
implantation, where reported, has range 59-72 years. Sample demographic 
details appear to be consistent across the studies and most likely reflect the 
epidemiology of heart failure. Most of the studies provide details of cardiac 
morbidity at entry to the study (Table 1). 
Study size 
The three largest studies [3;4;6] report on over 1000 CRT-D s, the largest 
being the Landolina study (n = 1726) [4]. The three smaller studies have CRT-
D sample sizes ranging from 90 to 621 participants [1;2;5;7]. 
Intervention 
All of the six longevity studies [1-7] evaluate CRT-D devices (Table 2). In the 
von Gunten study [6], only 26.3% of devices studies are CRT-Ds, however the 
results are presented distinctly for this subgroup (n = 1284 devices) so the 
data are useable. The remainder of devices in this study are other CIEDs: 
VVI-ICDs (44.2%), DDD-ICDs (27.4%) and subcutaneous ICDs (2%), which 
are not part of the decision problem. However a supplement to this paper 
reports longevity for 76 ENDURALIFE-powered COGNIS CRT-Ds. 
All of the studies recruited participants undergoing de novo CRT-D 
implantation and in addition, the Ellis study includes a proportion of patients 
undergoing device replacement / revision procedures (44%) as did the 
Landolina study (38%). 
The vast majority of CRT-Ds studied are provided by five manufacturers. Of 
these three (Boston Scientific, Medtronic, St Jude Medical) are better 
represented in the studies, and two (Sorin (non Liva Nova) and Biotronik) 
have fewer CRT-D cases included in the studies. There is therefore much less 
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published, empirical data on the longevity of Sorin/Liva Nova and Biotronik 
CRT-Ds, however PPR data exist for all devices (see Sections 3.3. and 3.6). 
Authors of longevity studies do not report reasons why a particular 
manufacturer’s CRT-D device was implanted according to patient factors. 
However the Ellis study notes a trend by which patients undergoing de novo 
implantation were more likely to receive Boston Scientific (2.0 Ah battery 
capacity) CRT-Ds whereas patients undergoing replacement procedures were 
more likely to receive Medtronic (1.0 Ah battery capacity) CRT-Ds, (p = 
0.053). 
A limitation of some of the studies is that not all Boston Scientific CRT-Ds are 
powered by the ENDURALIFE battery technology, thus limiting applicability to 
the decision problem. The proportion of Boston Scientific CRT-Ds is shown 
below: this limitation is compounded by the fact that it is the studies published 
in full that have this limitation to a greater degree: in von Gunten only 39% of 
Boston Scientific CRT-Ds are ENDURALIFE-powered CRT-Ds. However a 
supplement to this paper reports longevity for 76 ENDURALIFE-powered 
COGNIS CRT-Ds. 
In some instances the company has requested and received personal 
communication from authors to ascertain the proportion of Boston Scientific 
devices that were powered by ENDURALIFE battery technology. For example 
this was not reported in the Ellis study, whereas the company submission 
reports that 97% of Boston Scientific CRT-Ds were ENDURALIFE-powered 
CRT-Ds. 
Table 2: proportion of devices in longevity studies that are CRT-Ds 
Study % CRT-D 
(entire 
study 
cohort) 
% of Boston Scientific CRT-
Ds studied that are 
ENDURALIFE-powered CRT-
Ds 
Is longevity 
reported for 
the CRT-D 
subgroup? 
Alam [1;2] 100% 122/173 = 70.5% (as reported 
in the paper) 
122/188 = 64.9% (as advised 
by the company) 
N/A 
Ellis [3] 100% Not reported in study, though 
implant period is coterminous 
N/A 
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with the period since market 
launch of ENDURALIFE 
battery technology. 
The Company’s submission 
states that 312/322 = 97% of 
BSC devices were 
ENDURALIFE-powered CRT-
Ds. 
Landolina 
[4] 
100% 291/608 = 47.9% (paper also 
reports on a subgroup of 
modern generation devices 
including the ENDURALIFE-
powered CRT-Ds (n = 291) 
N/A 
Lau [5] 100% 100% N/A 
von 
Gunten 
[6] 
1284/4881 = 
26.3% 
102/259 = 39.4% 
Reports separately for 76 
ENDURALIFE-powered 
COGNIS CRT-Ds. 
Yes 
Williams 
[7] 
100% Not reported. Company’s 
submission states 51/53 = 
96.2% 
N/A 
The Company uses, in the economic model, the Landolina data for the latest 
generation of CRT-Ds in the study period (Landolina 2016, unpublished). 
These are the subgroup of ENDURALIFE-powered COGNIS CRT-Ds (note: 
both Landolina papers are derived from the same series of patients. It is 
unclear why in the first paper [4] there are 291 COGNIS devices and in the 
second paper (Landolina 2016, unpublished) there are 376 COGNIS devices). 
The EAC accepts that the Landolina data represent ENDURALIFE-powered 
CRT-Ds. 
Follow-up 
Average follow up in the six longevity studies ranges from 3.4-4.4 years. The 
latest point of follow-up for reporting of CRT-D longevity is at 6 years in the 
Lau study, available as an abstract only [5]. 
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Analysis method 
The longevity studies use actuarial methods to analyse cumulative survival 
probability e.g. Kaplan-Meier, with statistical significance assessed with the 
log-rank test. The analysis typically censors patients for competing events, 
including death, device replacement for infection or generator/lead 
malfunction and heart transplantation (Alam 2014). Covariates that can affect 
time to battery depletion are typically analysed using a Cox proportional 
hazards model. (Alam 2014). 
In contrast to PPRs (see below) the device survival longevity studies consider 
any type of battery depletion, regardless of whether it is normal or premature. 
Outcomes 
The studies report battery depletion (ERI) without reference to whether this is 
classified as premature, versus normal battery depletion (the definition applies 
only to PPRs and is discussed in Section 3.4). In practical terms this is not a 
limitation; the PPRs demonstrate that malfunctions, including premature 
battery depletion, are rare events.  
Methodology: published studies reporting complications due to 
replacement procedures 
Of the 19 studies included in the Company’s submission, three [8;11;12] are 
systematic reviews which include data from the majority of the same body of 
primary studies. To avoid presenting the same data twice, The EAC selected 
the three systematic reviews plus two primary studies [13;14] not included in 
the systematic reviews, for consideration as evidence on complications.  
One of these primary studies [14] is an analysis of health care claims data 
from the Truven Health analytics MarketScan Commercial Research 
Database in the US, based on 45,252 patients who underwent CIED 
replacement. 
The second primary study [13] utilised patients enrolled on the ALTITUDE 
project, an initiative to prospectively analyse data obtained from implanted 
Boston Scientific ICD and CRT devices, including 7458 cases ICD generator 
replacement. 
The Danish cohort study identified by clinical experts [9] is a large, 
retrospective analysis of a cohort of 5918 patients who underwent a CIED 
procedure in 14 centres in Denmark between May 2010-April 2011. Because 
a clinical expert plus the EAC consider this to be a robust source of data on 
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complications associated with CRT-D replacement, the EAC undertook data 
extraction (Tables 11-13) and critical appraisal (Appendix 4). 
The EAC considers applicability to CRT-D replacement procedures is limited 
only to a small extent by the inclusion of data for replacement of ICDs 
because in either case the procedure is essentially the same.  
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Table 3: Study characteristics of Danish retrospective cohort study [9] 
Study & 
country 
Patient population  CRT-D 
devices 
studied 
Study design Sample size EAC comments 
Kirkfeldt 
2014 
Denmark 
 
5918 patients who underwent a 
CIED procedure between May 
2010-April 2011 
Gender 
Male: 3707/5918 = 63% 
Female: 2211/5918 = 37% 
Age 
Median 74 (IQR 65-83) years 
CIED type 
Single-chamber PM: 1160/5918 
(20%) 
Dual-chamber PM: 3029/5918 
(51%) 
CRT-P: 209/5918 (4%) 
Single-chamber ICD: 684/5918 
(12%) 
Dual-chamber ICD: 391/5918 
(7%) 
CRT-D: 445/5918 (8%) 
Procedure type 
New implant: 4355/5918 (74%) 
Generator replacement: 
1136/5918 (19%) 
System upgrade or lead revision: 
427/5918 (7%) 
Device 
names not 
reported 
Retrospective cohort, 
multi-centre (14 centres in 
Denmark. 
 
Included 
Total n = 5918 
Excluded 
Patients with 
epicardial systems 
(n=24). 
Full journal article. No exclusion criteria were listed and the only inclusion 
criterion was patients who underwent a CIED procedure. Complications 
were presented for device type but were not manufacturer specific. 
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Methodology: Product Performance Reviews 
The US Heart Rhythm Society Task Force recommended production of PPRs 
for all market-approved implantable cardiac pulse generators or leads. PPR 
production has been taken up by all manufacturers of CRT-D devices. The 
international standard ISO 5841-2:2014 (E) specifies the required content of 
PPRs. The EAC accessed the relevant British standard: BS ISO 5841-2:2014 
in order to understand the process behind PPR production. Annex A of this 
standard defines the statistical method for device survival analysis. 
Production of PPRs relies on efforts to track the key events in the life course 
of a CRT-D device, including implant date, specific events during the device’s 
service life, and return of the device to the manufacturer for analysis following 
explantation. Annex A of BS ISO 5841-2:2014 defines the following categories 
that apply to a CRT-D device following implantation: 
 Category A: Device that is in service. No complication recorded or 
malfunction confirmed by returns analysis. 
 Category B: Device removed from service for reasons not related to the 
functioning of the device. No complication recorded or malfunction 
confirmed by returns analysis. 
 Category C1: Devices with a malfunction confirmed by returned 
product analysis or leads with a reported complication. 
 Category C2: Pulse generator battery depleted. No malfunction 
confirmed by returns analysis. 
 Category D: Patient has died. However, the death, as far as can be 
verified, is unrelated to the functioning of the device. No complication 
recorded or malfunction confirmed by returns analysis. 
 Category L: Device is lost to follow-up. No complication recorded or 
malfunction confirmed by returns analysis. 
Based on knowledge of the status of CRT-D devices observed during follow-
up and at device return, actuarial statistical methods are used to derive a 
cumulative survival probability. Thus comparison of PPRs across 
manufacturers may permit comparisons of CRT-D longevities. 
PPRs report survival probability in two ways; both are based on real, 
observed data. Firstly survival probability can include survival free from both 
malfunction and normal battery depletion. Secondly survival probability is also 
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reported as survival free of malfunction alone leading to explantation i.e. 
cases of normal battery depletion are excluded from the analysis. 
Importantly in either case the definition of ‘normal battery depletion’ is a 
function of the manufacturer’s predicted longevity. Predicted longevity is the 
anticipated device life based on developmental bench testing prior to 
releasing the CRT-D to market. It is important to note that this occurs under 
specific, controlled conditions which may not necessarily occur in clinical use. 
The specific controlled conditions also differ by manufacturer. 
‘Normal battery depletion’ is defined in BS ISO 584-2:2014 as follows: 
“(a)....implant time that meets or exceeds the nominal (50 percentile) 
predicted longevity at default (labelled) settings, or (b) a device is returned 
and the device has reached its elective replacement indicator(s) with implant 
time exceeding 75% of the expected longevity using the longevity calculation 
tool available at time of product introduction, calculated using the device’s 
actual use conditions and settings. 
Note that failure of a CRT-D due to early battery depletion, i.e. not meeting 
the criteria for normal battery depletion above, is always considered a 
malfunction. 
The EAC discussed with the company the methods used in the production of 
PPRs and acknowledges that PPRs have limitations in enabling direct 
comparisons between companies as follows: 
 Boston Scientific PPRs are based on implants within the US due to a 
higher level of reporting within the US than internationally.  
Malfunctions of devices from other countries are recorded, but they are 
not used in the survival calculations in PPRs. However the Company 
considers the US data to be generally representative for worldwide 
performance of Boston Scientific CRT-Ds.  
 Not all devices are returned to the manufacturer following explantation. 
The Boston Scientific PPR supplied in the company’s submission 
reports that in the period 2008-2015, between 58% and 68% of 
explanted CRT-Ds were returned to the company for analysis.  
 PPR analysis assumes that a device is in-service unless otherwise 
indicated. A risk exists whereby explanted CRT-Ds that are not 
returned to the manufacturer may be classified as Category A, above, 
instead of Category L (lost to follow-up). This would overestimate CRT-
D longevity. Neither the company nor the EAC is aware of any data on 
how well the different manufacturers correctly classify CRT-Ds that are 
either still in service or lost to follow-up. 
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 The definition of normal battery depletion means that two devices from 
different manufacturers that reach a point of battery failure at the same 
length of follow-up may be classified as normal battery depletion or 
premature battery depletion (a malfunction). For this reason the 
survival probability based on combined malfunction plus normal battery 
depletion is the better outcome for comparison. 
 PPRs report both malfunctions with CRT-D generators and also the 
leads (which are medical devices in their own right). These are 
reported separately. The company’s submission includes only data on 
generators, in line with the scope.  
3.5 Overview and critique of the Company’s critical appraisal 
The company has completed critical appraisal checklists for the included 
studies. These confirm that the studies are acceptable evidence, though they 
do not bring out the key features of the evidence, which is discussed 
elsewhere in the company’s submission and in this report. 
3.6 Results  
Published studies comparing CRT-D longevity across manufacturers 
All of the published retrospective studies of CRT-D longevity in the 
Company’s submission, presenting head-to-head comparisons of CRT-D 
devices from different manufacturers, provide evidence that the 
ENDURALIFE-powered CRT-D devices have better longevity than 
comparator CRT-D devices. The six studies of CRT-D longevity [1-7] have an 
average (mean or median) follow-up of between 3.0 years [3] and 6 years [5]. 
Four of the studies are published as full journal articles [1-4;6], with an 
average (mean or median) follow-up period of between 3.0 years [3] and 4.4 
years [6]. 
The Landolina study [4] and the von Gunten study present results for the sub 
group of CRT-Ds considered as ‘recent generation’ (defined as market 
release date 2007 onwards in the  Landolina study and as implant date from 
2006 onwards in the von Gunten study). These analyses demonstrate that 
CRT-D longevity improved over time, however the recent generation CRT-Ds 
studied, implanted between 2008-2010 (Landolina) and 2006-2014 (von 
Gunten) may have been superceded by devices marketed today. 
Alam [1;2] 
In the most recent publication from the study by Alam et al. with a mean 
follow-up of 3.4 years, rates of CRT-D replacement due to battery depletion 
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were Boston Scientific: 16%, St Jude Medical: 53%, Medtronic: 51%; p<0.001. 
The hazard ratios for battery depletion (adjusted for unbalanced electrical 
pacing parameters) were as follows: Boston Scientific:Medtronic 0.11 (95% CI 
0.07,0.16) p < 0.001, Boston Scientific:St Jude Medical 0.25 (95% CI 0.13, 
0.47) p < 0.001. Among patients with six years follow-up rates of battery 
survival were BCS: 77%, St Jude Medical: 44%, Medtronic: 10%.  
Ellis [3] 
In the study by Ellis et al. at a mean follow-up of 3.0 (SD 1.3) years, rates of 
CRT-D devices reaching ERI were as follows: Boston Scientific: 0.30%, St 
Jude Medical: 3.8%, Medtronic: 13.5%. Mortality rates in each manufacturer 
group were: Boston Scientific: 28.0%, St Jude Medical: 16.7%, Medtronic: 
21.8%. No CRT-D device failures were observed. High left ventricle lead 
impedance was protective of reaching ERI: OR (>1000 versus 500 Ohms) 
0.38, 95% CI 0.20, 0.71, p = 0.0025. 
Landolina [4] 
The study by Landolina et al. had a median follow-up of 3.6 (IQR 1.5, 4.4) 
years. Rates of battery depletion were as follows: Boston Scientific: 18%, St 
Jude Medical: 20%, Medtronic: 29%, Biotronik: 20%, Sorin: 20%. Rates of 
CRT-D device replacement (any cause) were as follows: Boston Scientific: 
22%, St Jude Medical: 24%, Medtronic: 34%, Biotronik: 20%, Sorin: 22%. 
Mortality rates were as follows: Boston Scientific: 18%, St Jude Medical: 16%, 
Medtronic: 14%, Biotronik: 12%, Sorin: 14%. Among CRT-D devices classified 
as recent generation (for the most part released to market after 2007) and 
excluding Biotronic CRT-Ds and Sorin CRT-Ds due to there being fewer than 
100 implants: the rates of devices still in service at five years were as follows: 
Boston Scientific: 88%, St Jude Medical: 75%, Medtronic: 52%; p<0.01. In 
multivariate analysis, factors associated with CRT-D replacement due to 
battery depletion were: manufacturer: HR Boston Scientific:Medtronic 0.64, 
95% CI 0.47,0.89, p = 0.008; recent generation device: HR recent:older 0.57, 
95% CI 0.45, 0.72, p = 0.001; Battery chemistry: HR Li/MnO2:Li/SVO 0.37, 
95% CI 0.22,0.64 p = 0.001; HR Li/CFx-SVO:Li/SVO 0.28, 95%CI 0.16, 0.50, 
p = 0.001; High left ventricle lead output (pulse amplitude > 2.5V, duration > 
0.5 ms) HR high:low 1.96, 95% CI 1.57,2.46, p = 0.001; unipolar left ventricle 
lead: HR unipolar:non-unipolar  1.58, 95% CI 1.25, 2.01, p = 0.001. 
von Gunten [6] 
The study by von Gunten et al. had a median follow up of 4.4 (IQR 2,7.3) 
years. Rates of CRT-D replacement were Boston Scientific: 30.9%, St Jude 
Medical: 22.1%, Medtronic: 36.3%, Biotronik: 10.1%, Sorin: 0%, (a total of 4 
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Sorin CRT-Ds were studied). In devices implanted from the year 2006 
onwards, five year longevity rates were as follows: Boston Scientific: 97.6%, 
St Jude Medical: 45.3%, Medtronic: 74.1%, Biotronik: 76.2%. Also in devices 
implanted from the year 2006 onwards, six year longevity rates were as 
follows: Boston Scientific: 97.6, St Jude Medical: 26.5, Medtronic: 46.3, 
Biotronik: 44.9. The rate of five year overall survival in patients with CRT-Ds 
(all manufacturers) was 72.8%. The rate of five year longevity of CRT-Ds 
implanted from 2006 onwards (all manufacturers) was 66.3%. In the sub 
group of 76 ENDURALIFE-powered COGNIS CRT-Ds there was 1 
replacement representing 97.5% longevity at 4 years following implantation. 
Lau [5] 
This study is available as an abstract. At six years follow up Boston Scientific 
CRT-D devices had 100% survival. St Jude Medical CRT-Ds began to reach 
ERI after 2.8 years and Medtronic CRT-Ds after 2.5 years. 
Williams [7] 
This study is available as an abstract. At four years follow up the rates of 
CRT-D devices reaching ERI were as follows Boston Scientific: 1.9%, St Jude 
Medical: 10%, Medtronic: 50%. In multivariate analysis CRT-Ds reaching ERI 
had higher right ventricle lead output, left ventricle lead output and right 
ventricle pulse width (no values reported). 
Results: published studies reporting complications due to replacement 
procedures 
Lewis et al. (2016) conducted a systematic review to determine the risks and 
benefits of ICD generator replacement. A total of seventeen studies 
(n>167,000 patients) were included in the final systematic review. 
Complications reported included: major complications (death and any 
complication that placed the patient at significant risk, required hospitalisation 
or surgical intervention) and minor complications (any other complication 
associated with significant symptoms or a decline in status not requiring 
surgical intervention e.g. incisional infection and pocket haematoma). The 
median rate for major complications was 4.05% (range: 0.55-7.37%). Infection 
requiring antibiotic therapy and/or extraction was the most frequently reported 
major complication with a median rate of 1.70% (range: 0-5.23%). Other 
frequently reported major complications included: haematoma requiring 
evacuation (median 0.57%; range: 0-1.55%), reoperation for any other reason 
e.g. pocket erosion or device repositioning due to pain (median 1.56%; range: 
0.07-3.24%) and stroke (median 0.45%, range 0.01-0.82%). The median rate 
for minor complications was 3.5% (range: 0.36-7.37%) with the most 
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frequently reported being pocket haematoma (median 0.93%; range: 0.35-
3.49%). Other frequently reported minor outcomes included: incisional 
infection (median 0.9%; range: 0.01-1.77%) and discomfort or pain at the site 
(median 0.44%; range: 0.39-0.45%). 
Polyzos et al. (2015) conducted a systematic review and meta-analysis to 
determine risk factors associated with cardiac implantable electronic device 
(CIED) infection. Their systematic review identified sixty studies which were 
relevant to their scope with a total of 233,184 patients. The average reported 
device infection rate for included prospective studies was 1.6% (n=21 
studies), 1% for included case-control studies (n=9 studies) and 1.2% for 
included retrospective cohort studies (n=30 studies). Twenty studies reported 
the risk of infection associated with generator change (n=33,322 patients). 
The pooled odds ratio for device infection as a result of generator change was 
1.74 (95% CI [1.22-2.19]). Device replacement/revision was associated with a 
pooled odds ratio of 1.98 (95% CI [1.46-2.70]) for device infection. The 
authors conclude that a “decision to replace a device should be made on a 
risk vs. benefit approach weighting the risk for death due to device failure, the 
rate of device failure, and the risk for procedure-related death”. 
A systematic review and meta-analysis of the complications associated with 
the replacement of cardiac implantable electronic device generators, following 
US Food & Drug Administration (FDA) recall, was carried out by Zeitler et al. 
(2015). The systematic review included seven studies which met the authors’ 
inclusion criteria with a total of 1,435 patients. This systematic review’s 
primary end-point was major complications while mortality and 
reoperation/pocket revision were considered to be “other” end-points. Major 
complications were defined differently by the authors of the included studies; 
however, for the most part major complications were defined as: death, any 
complication requiring reoperation (infection, bleeding/haematoma, system 
malfunction or pain) and any complication associated with device 
replacement. One included study focused on outcomes of device generator 
replacement in paediatric and congenital patients; the meta-analysis carried 
out by the authors excluded this study. Device generator replacement 
following US FDA recall was associated with a combined major complication 
rate of 2.60% (95% CI [0.9-4.8%]). Five out of the seven included studies 
reported the rate of death following the replacement of device generators; 
meta-analysis of this outcome gave a mortality rate of 0.4% (95% CI [0.1-
1.1%]). Additionally, five out of the seven included studies reported the rate of 
reoperation/pocket revision; meta-analysis of this outcome gave a rate of 
2.7% (95% CI [0.8-5.1%]). The authors conclude that generator replacement 
in response to a recall from the US FDA has a similar rate of major 
complications as elective generator replacement. Additionally, the authors 
conclude that patient and device characteristics, patient preference and 
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remaining battery life should all be considered when carrying out generator 
replacement, elective or otherwise.  
The incidence of lead damage following CIED replacement procedures and its 
economic impact was investigated by Nichols et al. (2016). In their study the 
authors reviewed health care claims data from the Truven Health analytics 
MarketScan Commercial Research Database in the US. The study cohort 
included 45,252 patients who underwent CIED replacement: 22,557 (50%) 
pacemaker generator replacements, 20,632 (46%) ICD generator 
replacements and 2,063 (5%) CRT-D generator replacements. Lead damage 
was observed in 406 patients (0.90%) at a median of 107 days following 
generator replacement. Lead damage incidence was 0.46% for patients with 
pacemakers, 1.27% for patients with ICDs and 1.94% for patients with CRT-
Ds. In a Cox proportional hazards model, where patient demographic and 
clinical characteristics were controlled for, ICD replacement showed double 
(hazard ratio (HR) 2.00, 95% CI [1.57-2.55]) the risk of lead damage and 
CRT-D replacement showed >2.5 times (HR 2.58, 95% CI [1.73-3.83]) the risk 
of lead damage compared with pacemaker replacement. Out of the 406 
patients with lead damage, 368 (91%) were in-patients and a median length of 
stay for lead damage was 3 days; this did not significantly differ based on the 
device type. The mean cost of lead damage management across the first year 
was $25,797; averaged across all device types. Lead damage management 
costs were significantly different across device types. Mean total 
hospitalisation costs were $19,959 for pacemaker replacement, $24,885 for 
ICD replacement and $46,229 for CRT-D replacement (p=0.048). The authors 
conclude that the higher rates of lead damage observed in ICD and CRT-D 
replacement are likely to be attributable to the greater number of and 
complexity of leads in ICDs and CRT-Ds.  
The risk of lead alerts following ICD generator replacement was investigated 
by Lovelock et al. (2014). This study utilised patients enrolled on the 
ALTITUDE project, an initiative to prospectively analyse data obtained from 
implanted Boston Scientific ICD and CRT devices. Data is collected through 
Boston Scientific’s LATITUDE home monitoring system. A total of 60,219 
patients were eligible for inclusion in this study, of which 7458 patients 
(12.4%) underwent ICD generator replacement. A time dependent Cox 
proportional hazards model (adjusted for age, gender and ICD type) was used 
to evaluate potential associations between lead failure and generator 
replacement. Lead performance in the 7458 patients undergoing generator 
replacement was compared to leads of similar age (68 months) in patients 
who did not undergo generator replacement. Patients who underwent 
generator replacement showed a 5-fold higher lead alert rate (HR 5.20, 95% 
CI [3.45-7.84]) when compared to those who did not; this was significantly 
different (p<0.001) even when covariates were adjusted for. Younger age and 
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single lead ICD systems were also associated with an increase in lead alerts, 
HR 1.02, 95% CI [0.98-0.99] (p<0.001) and HR 2.49, 95% CI [1.96-3.17] 
(p<0.001) respectively. However, both age and system type was associated 
with lead alert to a lesser extent than generator replacement. The authors 
suggest that surveillance is required following generator replacement in 
addition to technique development and lead modifications to minimise the risk 
of lead damage during surgery. In another study Lovelock et al. (2012) 
reported that the rate of failure in Medtronic Fidelis leads was 20.8% following 
ICD generator replacement and 2.5% in lead age-matched controls (p<0.001). 
The results of the Danish cohort study [9] identified to the EAC by a clinical 
expert are shown in tables 11, 12 and 13. 
Results: Product Performance Reviews 
The company’s submission provides the results of PPRs in Table B9 (page 
65). These indicate: 
 There is high variability in the selected follow-up points chosen across 
manufacturers for reporting of device longevity 
 When device survival excludes normal battery depletion i.e. survival 
free from device malfunction only (where malfunction includes early 
battery depletion), device survival is high at practically all follow-up 
points: 94% and above. This means that device malfunctions are rare 
events. 
 When device survival is considered as survival free from normal battery 
depletion plus malfunction: devices are observed to require 
replacement as time progresses i.e. normal battery depletion is by far 
the most common reason for explantation of a CRT-D. 
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Table 4 Results of Alam 2016: published observational study reporting battery survival 
Study Alam 2016 (an update of the same cohort reported as Alam 2014 shown below) 
Follow-up 
Mean 3.4 (SD ±2.1) years, median 3.7 (IQR 1.6, 5.0) years 
Battery & device 
longevity 
At mean follow-up 3.4 (SD 2.1) years: 
Rates of replacement due to battery depletion (ERI): 
Boston Scientific: 16% 
Medtronic: 51% 
St Jude Medical: 53% 
p < 0.001 
Time to battery depletion (unadjusted): 
HR (SJM:MDT) 0.46 (95% CI 0.31, 0.68) p < 0.001 
HR (BSC:MDT) 0.15 (95% CI 0.10,0.22) p < 0.001 
HR (BSC:SJM) 0.28 (95% CI 0.16, 0.48) p < 0.001 
Time to battery depletion (adjusted for unbalanced electrical pacing parameters): 
HR (SJM:MDT) 0.36 (95% CI 0.24, 0.54) p < 0.001 
HR (BSC:MDT) 0.11 (95% CI 0.07,0.16) p < 0.001 
HR (BSC:SJM) 0.25 (95% CI 0.13, 0.47) p < 0.001 
Kaplan-Meir analysis of CRT-D battery longevity 
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Study Alam 2016 (an update of the same cohort reported as Alam 2014 shown below) 
 
Percentage battery survival (%)by manufacturer: observations during follow-up 
versus PPR estimations 
 Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 
Observed battery survival 
Boston 
Scientific 
100 98 98 95 90 77 
Medtronic 100 99 92 74 36 10 
St Jude 
Medical 
100 100 100 90 69 44 
PPR estimated battery survival 
Boston 
Scientific 
100 100 100 99 98 98 
Medtronic 100 98 93 81 62 34 
St Jude 
Medical 
100 99 98 95 87 66 
Absolute % difference 
Boston 
Scientific 
0 2 2 4 8 21 
Medtronic 0 -1 1 7 26 24 
St Jude 
Medical 
0 -1 -2 5 18 22 
For all manufacturers, PPR reports overestimated battery longevity, particularly beyond 4 
years from device implantation. 
Factors associated 
with longevity 
Not reported 
CRT-D configuration Not reported 
EAC comments Full journal article. Losses to follow up since the publication of Alam 2014 seem to be 
patients with Medtronic CRT-D devices (n = 25). In the Boston Scientific group loss to follow 
up for 2014 (n = 32) versus 2016 (n = 31) must represent a minor error. Of 173 Boston 
Scientific devices studied, 122 were powered by ENDURALIFE battery technology, so 
comparisons by manufacturer do not have complete applicability to the scope. 
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Table 5 Results of Ellis 2016: published observational study reporting battery survival 
Study Ellis 2016 
Follow-up 
Mean 3.0 (SD ±1.3) years (with no substantial difference between manufacturers) 
Battery & 
device 
longevity 
Kaplan-Meier survival analysis: device survival function for battery depletion  
 
 
Device survival and out-of-service reason 
 
 
Overall  2.0 Ah (BSC)  1.4 Ah (SJM) 1.0 Ah (MDT) 
Battery reached ERI  8.80% 0.30% 3.80% 13.50% 
 
115/1,302 1/322 7/186 107/794 
Patient death  22.60% 28.00% 16.70% 21.80% 
 
294/1,302 90/322 31/186 173/794 
Device revision  1.10% 0.60% 0.50% 1.40% 
 
14/1,302 2/322 1/186 11/794 
Heart transplant  1.10% 1.60% 0.50% 1.00% 
 
14/1,302 5/322 1/186 8/794 
CIED infection  1.20% 0.90% 0.50% 1.40% 
 
15/1,302 3/322 1/186 11/794 
Other (device or lead failure)  2.30% 1.20% 1.60% 2.90% 
 
30/1,302 4/322 3/186 23/794 
 
No device failures were observed in the study. The general pattern of devices reaching ERI by 
manufacturer were similar when analysed for low LV pacing output and high LV pacing output 
(defined as exceeding 3V@1.0ms).  
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Study Ellis 2016 
Factors 
associated 
with longevity 
Univariate device parameters as predictor of ERI 
 
OR 95% CI  p 
Ah by manufacturer (MDT 1.0 Ah vs BSC 2.0 Ah and SJM 1.4 
Ah)  9.73 4.70, 20.15  <0.0001 
LRL: 
   <51 versus (51-61)  0.94 0.51, 1.72  0.8374 
<51 versus (61-71)  0.62 0.33, 1.18  0.1426 
<51 versus 71+ 0.72 0.47, 1.11  0.1358 
LV Impedance: 
  >1,000 versus 500  0.38 0.20, 0.71  0.0025 
>1,000 versus (500-700)  1.34 0.66, 2.73  0.4199 
>1,000 versus (700-1,000)  0.71 0.35, 1.42  0.3275 
BiV pacing: 
  <70 versus (70-80)  0.5 0.04, 5.76  0.5782 
<70 versus (80-90)  0.36 0.04, 3.1  0.3527 
<70 versus (90-95)  0.31 0.04, 2.45  0.266 
<70 versus (95-100)  0.43 0.08, 2.18  0.3067 
 
Additional CRT-D programming predictors of ERI 
 Overall  2.0 Ah  1.4 Ah  1.0 Ah  p 
Presence of atrial fibrillation  40.20% 41.20% 45.20% 38.60
% 
0.252 
 512/1,274 131/31
8 
80/177 301/77
9 
 
LV threshold >3 V @ 1.0 ms  9.90% 13.80% 9.60% 8.30% 0.025 
 123/1,246 43/312 17/177 63/757  
High shock/ATP burden* (>3 shocks)  19.30% 22.30% 10.50% 19.30
% 
0.288 
 91/472 23/103 Apr-38 64/331  
BiV pacing percentage >95%  75.00% 61.50% 76.00% 80.30
% 
<0.001 
 938/1,251 193/31
4 
133/17
5 
612/76
2 
 
85-95%  16.00% 27.10% 11.40% 12.50
% 
 
 200/1,251 85/314 20/175 95/762  
<85%  9.00% 11.50% 12.60% 7.20%  
 113/1,251 36/314 22/175 55/762  
Atrial pacing percentage <25%  53.90% 62.00% 54.90% 50.20
% 
0.01 
 570/1,058 168/27
1 
84/153 318/63
4 
 
25-75%  28.50% 26.20% 27.50% 29.80
% 
 
 302/1,058 71/271 42/153 189/63
4 
 
>75%  17.60% 11.80% 17.60% 20.00
% 
 
 186/1,058 32/271 27/153 127/63
4 
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Study Ellis 2016 
CRT-D 
configuration 
Device parameters 
Parameter 2.0 Ah (BSC)  1.0 Ah (MDT)  1.4 Ah (SJM)  Overall  p 
LRL (low rate limit)  61.16 ± 8.90  62.38 ± 8.43  62.21 ± 7.26  62.05 ± 8.41  
0.090
2 
LV impedance  
715.88 ± 
261.73  
606.74 ± 
269.51  
662.75 ± 
249.46  
643.94 ± 
268.01  
0.000
3 
Atrial fibrillation at 
implant  41.20% 38.60% 45.20% 40.20% 
0.125
2 
Atrial pacing %  27.32 ± 30.89  35.06 ± 33.63  33.10 ± 34.13  32.80 ± 33.16  
0.005
6 
BiV pacing  92.83 ± 13.27  95.47 ± 12.44  93.59 ± 13.32  94.55 ± 12.82  
0.005
1 
Programmed parameters 
Parameter  Category  Overall  2.0 Ah (BSC)  1.4 Ah (SJM)  1.0 Ah (MDT)  p 
RV lead programmed 
pacing voltage 
Mean  2.24 ± 0.55  2.37 ± 0.5  2.23 ± 0.58  2.19 ± 0.55  <0.0001 
 Median  2.08 2.33 2.08 2.01  
 N  1,260 316 177 767  
RA lead pacing voltage Mean  2.07 ± 0.63  2.29 ± 0.55  2.12 ± 0.55  1.97 ± 0.66  <0.0001 
 Median  2 2.21 2 1.86  
 N  1,124 267 160 697  
RA lead impedance (Ω) Mean  486.2 528.8 ± 35.3  421.4 478.4 <0.001 
RV lead impedance (Ω) Mean  516.6 551.7 ± 113.1  455.6 510.3 <0.001 
 
EAC 
comments 
Full journal article. Authors report that the proportion of devices by manufacturer represents the 
market share distribution. No exclusions are reported. All device implant data were confirmed with 
manufacturers, including patients who transferred to long-term follow up at other centres. 
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Table 6 Results of Landolina 2015: published observational study reporting battery survival 
Study Landolina 2015 
Follow-up 
Median 43 months (IQR 18, 53) months i.e.3.6 (IQR 1.5, 4.4) years, 5201 person-years 
Battery & device 
longevity 
Batteries still in service at 5 years follow-up in recent generation devices (marketed post 2007) and 
with n > 100: 
Boston Scientific 88% 
Medtronic 52% 
St Jude Medical 75% 
p<0.01 
 
Kaplan-Meier analysis of device survival from replacement for battery depletion in recent generation 
devices (marketed post 2007) and with n > 100 
 
 
 
Number of patients with reported events 
 
Manufacturer n Median 
follow-up 
(IQR) 
All-cause 
replacement 
(%) 
Battery 
depletion 
(%) 
Deaths 
n (%)  
Incomplete 
follow-up, n 
(%) 
Biotronik  49  
49 [34 - 56]  10 (20)  10 (20)  6 (12)  2 (4) 
Boston 
Scientific  
608  
44 [16 - 55]  132 (22)  109 (18)  
112 
(18)  56 (9) 
Medtronic  798  
41 [18 - 52]  274 (34)  228 (29)  
115 
(14)  64 (8) 
Sorin  99  
47 [18 - 54]  22 (22)  20 (20)  14 (14)  8 (8) 
St Jude 
Medical  
172  
44 [18 - 55]  41 (24)  34 (20)  27 (16)  16 (9) 
 
40 CRT-Ds were removed due to device-related infection, 7 were removed at the time of heart transplant. 31 
generators were replaced at the time of lead failure or elective replacement of a non-malfunctioning safety 
advisory lead. 
 
For each manufacturer (except Biotronic, smallest group) newer generation devices had longer survival from 
replacement due to battery depletion, p<0.002. 
 
 
  45 of 115 
External Assessment Centre report: ENDURALIFE-powered CRT-D devices for the treatment of heart failure 
Date: July 2016 
Study Landolina 2015 
 
Factors 
associated with 
longevity 
Factors associated with replacement due to battery depletion 
 
Univariate analysis Multivariate analysis 
 
HR 95% CI p HR 95% CI p 
Biotronik  0.75 0.40 - 1.41 0.369 - - - 
Boston Scientific  0.54 0.43 - 0.67 0.001 0.64 0.47 - 0.89 0.008 
Medtronic  1 - - 1 - - 
Sorin  0.83 0.53 - 1.30 0.415 - - - 
St Jude Medical  0.74 0.52 - 1.05 0.089 - - - 
Recent generation  0.5 0.40 - 0.61 0.001 0.57 0.45 - 0.72 0.001 
Battery chemistry: Li/SVO  1 - - 1 - - 
Battery chemistry: Li/CFx-SVO  0.42 0.24 - 0.72 0.002 0.28 0.16 - 0.50 0.001 
Battery chemistry: Li/MnO2  0.2 0.13 - 0.33 0.001 0.37 0.22 - 0.64 0.001 
High right atrial lead output* 0.7 0.39 - 1.24 0.219 - - - 
High right ventricular lead output* 1.38 0.83 - 2.31 0.217 - - - 
High left ventricular lead output* 1.74 1.39 - 2.18 0.001 1.96 1.57 - 2.46 0.001 
Unipolar left ventricular lead  1.71 1.37 - 2.13 0.001 1.58 1.25 - 2.01 0.001 
True-bipolar right ventricular lead  1.47 1.21 - 1.79 0.001 1 0.78 - 1.30 0.978 
Percentage of biventricular pacing  1.2 0.91 - 1.58 0.207 - - - 
Shocks delivered  1.58 0.59 - 4.20 0.365 - - - 
Li/MnO2 Lithium manganese oxide 
Li/SVO lithium silver-vanadium oxide 
Li/CFx-SVO lithium silver-vanadium oxide and carbon monofluoride 
* defined as pulse amplitude > 2.5 V and duration > 0.5 ms 
 
In multivariate analysis of recent generation devices only, independent predictors of battery depletion were 
LV lead output (HR 3.09, 95% CI 2.18-4.38, p<0.001) and Boston Scientific CRT-Ds (HR 0.13, 95% CI 0.04-
0.40, p<0.001). 
 
CRT-D 
configuration 
Pacing output, % biventricular pacing and total number of shocks delivered 
 Biotronic Boston 
Scientific 
Medtronic Sorin St Jude 
Medical 
Patients with 
high
ǂ
 RA lead 
output (%) 
0  6 4 1 
Patients with 
high RV lead 
output (%) 
2 5 4 1 5 
Patients with 
high LV lead 
output (%) 
13 31* 18 31* 26* 
% of patients 
with 
biventricular 
pacing 
<90%/90-
95%/≥95% 
10/13/77 12/10/77 9/14/76 16/18/65 11/13/75 
% of patients 
with shocks 
delivered 0/1-
10/10-20/>20 
64/36/0/0 69/29/1/1* 85/13/0/1 83/17/0/0 74/26/0/0* 
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Study Landolina 2015 
ǂ defined as pulse amplitude > 2.5 V and duration > 0.5 ms 
* p < 0.05 vs Medtronic 
The proportion of patients with LV pulse amplitude < 2.5 V and duration < 0.5 ms was higher in the 
Medtronic group (p<0.05) and Medtronic patients were less likely to receive a shock. 
 
EAC comments Full journal article. Of 608 patients in the Boston scientific group 291 had the Cognis CRT-D i.e. 
48% were powered by ENDURALIFE battery technology. Paper does not report patient 
demographic and cardiac disease data. Although only 48% of BSC CRT-Ds were ENDURALIFE-
powered CRT-Ds, the analysis of recent generation devices (marketed 2007 onwards) appears to 
include only 29 Livian CRT-Ds, suggesting that 291/320 = 91% of recent generation BSC CRT-Ds 
were ENDURALIFE-powered CRT-Ds. 
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Table 7 Results of Lau 2015: observational study reporting battery survival (abstract) 
Study Lau 2015 
Follow-up 
6 years 
Battery & device 
longevity 
Boston scientific devices had 100% survival from ERI at 6 years. St Jude Medical devices 
began to reach ERI after 2.8 years and Medtronic after 2.5 years 
Pairwise comparisons of time to ERI: 
Boston Scientific versus St Jude Medical:  p = 0.0018 
Boston Scientific versus Medtronic:   p < 0.0001 
St Jude Medical versus Medtronic:   p = 0.00386 
 
Factors associated 
with longevity 
Not reported 
CRT-D configuration Not reported 
EAC comments Study available as abstract only: many details not reported, including patient factors, number 
of subjects per group and average follow-up. Non ERI events removing devices from service 
were censored. 
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Table 8 Results of von Gunten 2015: published observational study reporting battery 
survival 
Study von Gunten 2015 
Follow-up 
Median 53 (IQR 24-87) months i.e. median 4.4 (IQR 2-7.3) years 
 
Battery & device 
longevity 
CRT-D devices by manufacturer & replacements 
 n 
(implanted) 
n 
(replaced) 
% 
replaced 
Biotronic 228 23 10.1% 
Boston 
Scientific 
259 80 30.8% 
Intermedics 0 0 0% 
Medtronic 267 97 36.3% 
St Jude 
Medical 
526 116 22.1% 
Sorin ELA 4 0 0% 
Cameron 0 0 0% 
Total 1284 316 24.6% 
Survival of CRT-D devices (%) 
 Implanted pre-2006 Implanted 2006 onwards 
 5 year longevity 
(%) 
6 year longevity 
(%) 
5 year longevity 
(%) 
6 year longevity 
(%) 
Biotronic 0 0 76.2 44.9 
Boston 
Scientific 
43.5 17.5 97.6 97.6 
Medtronic 39.2 7.4 74.1 46.3 
St Jude Medical 61.5 30.9 45.3 26.5 
All 
manufacturers 
47.1 21.2 66.3 43.0 
In 76 ENDURALIFE-powered COGNIS CRT-Ds there was 1 replacement representing 
97.5% longevity at 4 years following implantation. 
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Study von Gunten 2015 
 
Kaplan-Meier analysis of CRT-D longevity: 887 CRT-Ds implanted from year 2006 
onwards 
 
 
Patient overall survival (all manufacturers & all ICD types): 
4-year 83.3% 
5-year 80.1% 
10-year 59.1% 
Factors associated 
with longevity 
Not reported 
CRT-D configuration Not reported 
EAC comments 
Full journal article. The paper reports on ICDs for out of scope patient indications including 
VVIs and DDDs in addition to CRT-D. The paper reports baseline characteristics 
(demographic, cardiac morbidity, NYHA class, medical therapies) for the entire cohort and 
not by analysis groups. Paper reports how many patients were censored due to competing 
risks (not reported by analysis group): 
822 died 
85 underwent heart transplant 
189 moved to other hospitals 
154 were lost to follow-up. 
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Table 9 Results of Alam 2014: published observational study reporting battery survival 
Study Alam 2014 
Follow-up 
Median (IQR): 
Overall:   3.1 (1.3-3.9) 
Boston Scientific: 3.0 (0.9-3.9) 
Medtronic:   3.1 (1.5-4.0) 
St Jude Medical: 3.2 (1.6-4.1 ) 
Battery & device 
longevity 
At overall mean follow-up of 2.7 (SD ±1.5) years: 
Of 122 ENDURALIFE-powered devices, 2 (1.6%) reached ERI and were replaced. 
Devices that were replaced due to reaching ERI 
Boston Scientific:  7/173 = 4% [ENDURALIFE-powered: 2/122 = 1.6%] 
Medtronic:   102/416 = 25% 
St Jude Medical:   4/57 = 7% 
p<0.0001 
4-year CRT-D device survival rate 
Boston Scientific:  94% 
Medtronic:   67% 
St Jude Medical:   92% 
p<0.001 
Kaplan-Meier survival analysis of CRT-D battery depletion 
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Study Alam 2014 
Factors associated 
with longevity 
Predictors of reaching ERI (adjusted for pacing burden, lead parameters in each chamber 
except for LV lead output and burden of ICD therapy) 
 OR (95% CI) p 
Manufacturer* 6.27 (2.53, 15.52) <0.001 
RA impedance 1.00 (1.00, 1.00) 0.762 
RV impedance 1.00 (0.99, 1.00) 0.786 
LV output 1.97 (1.64, 2.37) <0.001 
LV impedance 1.00 (0.99, 1.00) 0.036 
Proportion of patients receiving shock 1.29 (0.85, 1.95) 0.22 
* Medtronic versus others 
Patients whose batteries reached ERI had higher LV output (3.1+ 1.2 vs. 2.7+0.9 V, p < 0.001) and 
higher LV pulse width (0.8+0.4 vs. 0.6+0.3 ms, p < 0.001) compared with those who did not reach ERI. 
No other parameters were different between the devices reaching vs. not reaching ERI. This finding 
was present across all manufacturer groups. 
 
CRT-D configuration Device parameters 
 Boston Scientific Medtronic St Jude Medical 
RA output (V)  2.6±0.7 2.6±0.9 2.6±0.6 
RA pulse width (ms)  0.49±0.04 0.49±0.11 0.50±0.14 
RA impedance (Ω)*  493±195 604±596 396±67 
RA pacing burden 
(%)  21±33 25±34 20±29 
RV output (V)  2.8±0.7 2.6±0.8 2.8±0.7 
RV pulse width (ms)  0.50±0.04 0.52±0.21 0.53±0.12 
RV impedance (Ω)*  511±116 503±181 446±93 
RV pacing burden 
(%)  91±17 92±20 94±16 
LV output (V)*  2.9±0.9 2.7±1.0 2.7±0.8 
LV pulse width (ms)  0.69±0.34 0.65±0.31 0.75±0.38 
LV impedance (Ω)*  663±243 587±287 565±190 
LV pacing burden 
(%)  94±12 92±20 94±14 
Proportion of 
patients receiving 
any shocks 
including DFT 
testing (%)* 55 39 5.3 
Proportion of 
patients receiving 
anti-tachycardia 
pacing (%)* 30 16 11 
Patients implanted with Boston Scientific devices had highest programmed LV outputs and were most 
likely to receive device therapy. 
EAC comments Full journal article. Data suggest that all devices reaching ERI were replaced due to battery 
depletion. Of 173 Boston Scientific devices studied, 122 were powered by ENDURALIFE 
battery technology, so comparisons by manufacturer do not have complete applicability to 
the scope. 
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Table 10 Results of Williams 2014: observational study reporting battery survival (abstract) 
 
Study Williams 2014 (abstract) 
Follow-up 
Reported as 4 ± 0.8 years 
Battery & device 
longevity 
During 4 ± 0 8 years follow-up, 16 devices reached ERI (17 6%); CRT-Ds reaching ERI by 
manufacturer:  
BSC 1 / 53 (1 9%) 
MDT 14 / 28 (50%) 
SJM 1 / 10 (10%) 
(p < 0 001).  
Factors associated 
with longevity 
BSC had the highest RA lead impedance while MDT had the highest RV lead impedance 
(*p<0 05, 
1-way ANOVA) Covariates that can affect time to battery depletion were included in a 
multivariate Cox proportional hazard model; Patients reaching ERI had higher RV and LV 
output and RV pulse width (values not reported). 
CRT-D configuration 
 BSC MDT SJM 
RA Output (V)  2.2 ± 0.4 2.1 ± 1.1 
2.3 ± 
0.4 
RA Pulse Width (ms)  
0.52 ± 
0.08 
0.45 ± 
0.19 
0.53 ± 
0.09 
RA Impedance (Ohms)*  
516 ± 
109 476 ± 0 
400 ± 
47 
RA Pacing (%)  27 ± 37 27 ± 31 55 ± 28 
RV Output (V)  2.3 ± 0.5 2.4 ± 0.7 
2.4 ± 
0.3 
RV Pulse Width (ms)  
0.50 ± 
0.10 
0.54 ± 
0.15 0.50 ± 
RV Impedance (Ohms)*  
509 ± 
158 
549 ± 
188 
397 ± 
73 
LV Output (V)  2.3 ± 0.8 2.2 ± 1.4 
2.4 ± 
0.7 
LV Pulse Width (ms)  
0.76 ± 
0.32 
0.77 ± 
0.44 
0.75 ± 
0.35 
LV Impedance (Ohms)  
650 ± 
198 
685 ± 
488 
581 ± 
273 
BiV Pacing (%)  98 ± 2 91 ± 27 96 ± 5 
Shocks per Patient  1.5 ± 2 1.2 ± 0.9 
1.3 ± 
0.5 
* p < 0.05 
EAC comments Study available in abstract only: full details not reported, including values for some outcome 
data.  
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Table 11 Number of complications based on CIED type and procedure type from Danish cohort study [9] 
 
 Total (n=5918) No complications 
(n=5356) 
Complication (n=562) 
CIED type    
Single-chamber PM 1160 (20%) 1080 (20%) 80 (14%) 
Dual-chamber PM 3029 (51%) 2758 (52%) 271 (48%) 
CRT-P 209 (4%) 189 (4%) 20 (4%) 
Single-chamber ICD 684 (12%) 627 (12%) 57 (10%) 
Dual-chamber ICD 391 (7%) 336 (6%) 55 (10%) 
CRT-D 445 (8%) 366 (7%) 79 (14%) 
Procedure type    
New implant 4355 (74%)  3923 (73%) 432 (77%) 
Generator replacement 1136 (19%)  1069 (20%) 67 (12%) 
System upgrade or lead 
revision 
427 (7%)  364 (7%) 63 (11%) 
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Table 12. Cumulative incidence of complications at 6 months from Danish cohort study [9] 
 All 
(n=591
8) 
New implant 
(n=4355) 
Generator replacement 
(n=1136) 
Upgrade/lead revision 
(n=427) 
Any complication  
 
562 
(9.5; 
8.7–
10.2) 
432 (9.9; 9.0–
10.8)  
67 (5.9; 4.5–7.3)  63 (14.8; 11.4–18.1) 
Any major complication  329 
(5.6; 
5.0–
6.1) 
253 (5.8; 5.1–6.5)  40 (3.5; 2.4–4.6)  36 (8.4; 5.8–11.1) 
Any minor complication  250 
(4.2; 
3.7–
4.7) 
189 (4.3; 3.7–4.9)  30 (2.6; 1.7–3.6)  31 (7.3; 4.8–9.7) 
Major complications 
Lead related re-intervention  143 
(2.4; 
2.0–
2.8) 
120 (2.8; 2.3–3.2)  10 (0.9; 0.3–1.4)  13 (3.0; 1.4–4.7) 
Infection  49 
(0.8; 
0.6–
1.1) 
24 (0.6; 0.3–0.8)  17 (1.5; 0.8–2.2)  8 (1.9; 0.6–3.2) 
Local infection  22 
(0.4; 
0.2–
0.5) 
10 (0.2; 0.1–0.4)  8 (0.7; 0.2–1.1)  4 (1.0; 0.0–1.9) 
Systemic infection/endocarditis  27 
(0.5; 
0.3–
0.6) 
14 (0.3; 0.2–0.5)  9 (0.8; 0.3–1.3)  4 (0.9; 0.0–1.9) 
Pneumothorax requiring drainage  51 
(0.9; 
0.6–
1.1) 
45 (1.0; 0.7–1.3)  0 6 (1.4; 0.3–2.5) 
Cardiac perforation  38 
(0.6; 
0.4–
0.8) 
35 (0.8; 0.5–1.1)  0 3 (0.7; 0.0–1.5) 
No intervention  21 
(0.4; 
0.2–
0.5) 
18 (0.4; 0.2–0.6)  0 3 (0.7; 0.0–1.5) 
Intervention
b
  17 
(0.3; 
0.2–
0.4) 
17 (0.4; 0.2–0.6)  0 0 
Pocket revision because of pain  25 
(0.4; 
0.3–
0.6) 
10 (0.2; 0.1–0.4)  9 (0.8; 0.3–1.3)  6 (1.4; 0.3–2.5) 
Generator-lead interface problem with 
re-intervention  
7 (0.1; 
0.0–
0.2) 
3 (0.1; 0.0–0.1)  4 (0.4; 0.0–0.7)  0 
Haematoma requiring re-intervention  10 
(0.2; 
0.1–
0.3) 
9 (0.2; 0.1–0.3)  1 (0.1; 0.0–0.3)  0 
Other
c
  16 
(0.3; 
0.1–
0.4) 
16 (0.4; 0.2–0.5)  0 0 
Minor complications 
Haematoma
d
  138 
(2.3; 
1.9–
104 (2.4; 1.9–2.8)  20 (1.8; 1.0–2.5)  14 (3.3; 1.6–5.0) 
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2.7) 
Wound infection treated with antibiotics  69 
(1.2; 
0.9–
1.4) 
47 (1.1; 0.8–1.4)  12 (1.0; 0.5–1.7)  10 (2.3; 0.9–3.8) 
Pneumothorax conservatively treated  39 
(0.7; 
0.5–
0.9) 
32 (0.7; 0.5–1.0)  0 7 (1.6; 0.4–2.8) 
Lead dislodgement without re-
intervention  
10 
(0.2; 
0.1–
0.3) 
9 (0.2; 0.1–0.3)  0 1 (0.2; 0.0–0.7) 
Mortality 327 
(5.5%)
e
 
- - - 
a 
Reported as absolute frequencies and percentages with 95% CIs in parenthesis
 
b 
Lead revision, pericardiocentesis, or both. 
c 
Deep venous thrombosis (n=8), Twiddler’s syndrome (n=3), wound revision (n=3), stroke (n=1), myocardial infarction (n=1) 
d
 Resulting in prolonged hospital stay, hospital re-admission, or additional out-patient visit. 
e
 One death was possibly procedure-related. No other deaths were thought to be as a result of procedure-related causes.  
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Table 13 Predictors for complications from Danish cohort study [9] 
 
 Any major complication Any minor complication 
 Risk (%) Adjusted risk 
ratio (aRR)
b
 
(95% CI) 
P-value Risk (%) aRR
b
 (95% CI) P-value 
Gender 
Male
a
 5.0  – –  4 –  – 
Female 6.5  1.4 (1.2–1.8) 0.001 4.6 1.2 (0.9–1.5)  0.22 
Age group, years 
0–39 7.8  1.3 (0.7–2.2) 0.36 3 0.5 (0.2–1.5)  0.23 
40–59 7.2  1.1 (0.8–1.5) 0.38 4.8 1.0 (0.7–1.5)  0.94 
60–79
a
 6.3  – –  4.4 –  – 
≥80 3.7  0.6 (0.5–0.8) 0.001 3.9 1.0 (0.7–1.3)  0.81 
Body mass index, kg/m
2
 
Underweight (<18.5) 8.0  1.5 (0.8–2.5) 0.17 6.8 1.5 (0.8–2.8)  0.21 
Normal (18.5–24.9)a 5.6  – –  4.4 –  – 
Overweight (25–29.9) 5.3  0.9 (0.7–1.2) 0.41 3.7 0.8 (0.6–1.1)  0.15 
Obese (≥30) 5.2  0.8 (0.6–1.1) 0.13 4.6 0.9 (0.7–1.3)  0.7 
Centre volume 
0–249 5.7  1.4 (0.9–2.0) 0.13 2.9 1.7 (0.9–3.1)  0.09 
250–499 5.3  1.4 (1.0–2.0) 0.054 5.7 3.5 (2.2–5.4)  ,0.001 
500–749 6.4  1.2 (0.9–1.6) 0.19 5.2 2.1 (1.4–3.0)  ,0.001 
≥750
a
 5.0  – –  2.4 –  – 
CIED type 
Single-lead PM 3.3  0.7 (0.5–1.0) 0.03 3.7 0.9 (0.6–1.3)  0.66 
Dual-chamber PMa 5.5  – –  3.8 –  – 
CRT-P 6.7  1.6 (0.9–2.8) 0.11 3.8 1.5 (0.7–3.1)  0.3 
Single-chamber ICD 5.4  1.2 (0.8–1.8) 0.39 3.2 1.3 (0.8–2.3)  0.52 
Dual-chamber ICD 6.7  1.4 (0.9–2.2) 0.15 7.7 2.8 (1.7–4.5)  ,0.001 
CRT-D 11.0  2.4 (1.6–3.5) <0.001  7.4 2.8 (1.7–4.4)  ,0.001 
Procedure type 
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New implant
a
 5.8  – –  4.3 –  – 
Generator replacement 3.5  0.6 (0.5–0.9) 0.01 2.6 0.6 (0.4–0.9)  0.02 
Upgrade/lead revision 8.4  1.3 (0.9–1.8) 0.18 7.3 1.5 (1.0–2.3)  0.03 
Operator volume 
0–49 7.7  2.0 (1.3–3.1) 0.002 6.6 1.9 (1.2–3.1)  0.01 
50–99  5.7  1.3 (0.9–1.8) 0.11 3.2 0.8 (0.5–1.2)  0.24 
100–149 5.8  1.4 (1.0–1.8) 0.03 4.8 1.1 (0.8–1.5)  0.71 
≥150
a
 4.9  – –  3.9 –  – 
Procedure priority 
Elective
a
 5.5  – –  4.3 –  – 
Emergency, daytime 6.5  1.3 (0.8–2.0) 0.24 3.5 1.1 (0.6–2.0)  0.76 
Emergency, out-of-hours 7.2  1.6 (1.0–2.7) 0.07 4.5 1.4 (0.7–2.7)  0.32 
a
Reference group. 
b
Adjusted for gender, age, body mass index, centre volume, CIED type, procedure type, procedure priority, and operator volume. 
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3.7 Description of the adverse events reported by the Company 
The EAC identifies two considerations with regard to adverse events: 
 Complications that may arise from replacement procedures for CRT-
Ds. The most common reason for need for replacement is normal 
battery depletion [15-19]. These complications are discussed in Section 
3.4 and Section 3.6. 
 Adverse events that may arise at any time, simply because CRT-Ds 
are active implantable Class III medical devices. 
For the first category, complications associated with repeat procedures, the 
company undertook a second literature search which identified a body of 19 
relevant studies. These are discussed in Section 3.4 and Section 3.6. 
For the second category, adverse events, the company undertook a search of 
the US FDA MAUDE database and the UK MHRA database. The company 
provides a comprehensive description of adverse events identified, cited 
below: 
“8,226 adverse events reported for ENDURALIFE-powered CRT-D devices, of 
which 5,086 (62%) have been classified as device-related. The remainder are 
classified as non-device related adverse events relating to infection, erosion, 
migration or procedure-related complications. Battery or longevity issues 
account for 1,764 of the device-related adverse events (0.76% of all units sold 
worldwide). 1,492 have had Corrective Actions implemented or completed the 
Corrective and Preventive Action (CAPA) process with established thresholds 
for long term monitoring. Of the remaining, 213 were unconfirmed adverse 
events (no device returned for analysis) and 59 were not associated with a 
Pattern. Of the 1,764 battery or longevity adverse events, 1,333 can be 
attributed to a specific AVX Bypass Capacitor issue (subject to an advisory). 
Mitigations and Corrective Actions were implemented for CRT-Ds and ICDs of 
the COGNIS™, TELIGEN™, INCEPTA™, ENERGEN™, PUNCTUA™, 
AUTOGEN™, INOGEN™, DYNAGEN™ and ORIGEN™ families. To date, 
there have not been any identified failures related to this pattern for the more 
recent AUTOGEN, INOGEN, DYNAGEN or ORIGEN families.” 
EAC search for adverse events 
The EAC undertook its own search for adverse events. In the US FDA 
MAUDE database the EAC used the advanced search function and searched 
for the following brand names from 2008 to date: “ENDURALIFE” or 
“COGNIS” or “ENERGEN” or “PUNCTUA” or “INCEPTA” or “AUTOGEN” or 
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“INOGEN” or “DYNAGEN” or “ORIGEN”. This returned 2677 results as 
follows: 
 “ENDURALIFE” = 0 
 “COGNIS” >500* 
 “ENERGEN” >500* 
 “PUNCTUA” = 286 
 “INCEPTA” >500* 
 “AUTOGEN” = 171 
 “INOGEN” >500* 
 “DYNAGEN” = 224 
 “ORIGEN” = 26 
* The search facility displays a maximum of 500 records. Where the number of identified 
records exceeds 500, the user is urged to refine their search. 
The EAC also searched the UK MHRA database using the following terms: 
“Boston Scientific” or “CRT-D” or “cardiac resynchronisation therapy” or 
“ENDURALIFE” or “COGNIS” or “ENERGEN” or “PUNCTUA” or “INCEPTA” 
or “AUTOGEN” or “INOGEN” or “DYNAGEN” or “ORIGEN”. 
This identified two Medical Device Alerts as follows: 
 (Boston Scientific) Rapid battery depletion leads to risk of loss of 
therapy. (MDA/2014/039). Issued: 7 October 2014 
 (Boston Scientific) specific models of defibrillators implanted 
subpectorally have a risk of loss of shock therapy, inappropriate shock 
therapy, loss of pacing therapy or loss of anti-tachycardia pacing. 
(MDA/2010/012). Issued: 10 February 2010 
The first alert relates to Boston Scientific COGNIS CRT-Ds that had 
experienced an increased rate of premature battery depletion due to a 
problem with a low voltage (LV) capacitor. This affected an additional 885 UK 
patients to the previous total of approximately 1,000 UK patients identified in 
August 2013. The alert states that the manufacturer notified pacing clinics 
about the recent introduction of updated Safety Architecture software that will 
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improve early detection of the problem. The reported prevalence of failures 
was 2% at this report date. 
The second alert, which also applies to the COGNIS CRT-D, describes risks 
for subpectoral implants of: 
 loss of shock therapy 
 inappropriate shock therapy 
 loss of pacing therapy 
 loss of anti-tachycardia pacing 
The risk arises from physical damage to the CRT-D casing during 
implantation or subsequent force applied against the patient’s rib cage. The 
manufacturer has confirmed two (non-UK) reports of device malfunction 
associated with this issue out of approximately 77,000 devices sold 
worldwide. Both devices required early replacement (at four and five months 
post-implant) as they had delivered inappropriate shocks. The manufacturer 
recommended actions to clinicians which included active identification of 
patients who may be affected, changes to programmed configurations in 
affected CRT-Ds, patient counselling and follow-up, avoidance of future 
subpectoral implantation and potentially, CRT-D replacement. 
EAC conclusion on adverse events 
The company identified over 8000 adverse events relating to ENDURALIFE-
powered CRT-D devices, whereas the EAC identified 2677. 
The company is likely to be highly vigilant for adverse events for all of the 
implantable devices that it markets, and has likely identified more adverse 
events than the EAC by its own active surveillance and close communication 
with regulatory bodies and clinical sites.  
The EAC has not attempted to further categorise the large number of adverse 
events identified. The EAC considers that CRT-Ds are technologically 
advanced, active implantable, Class III medical devices with indications in 
patients at risk of serious morbid incident or mortality. Published evidence 
indicates that CRT-Ds improve patient survival [20], though due to their 
complex design and function, plus implantation in large numbers of patients 
globally, adverse events are to be expected across all manufacturers. High 
vigilance for adverse events is likely to be a feature of the entire CIED 
industry and the EAC is not aware of specific trends by which adverse events 
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related to CRT-Ds from any particular manufacturer are more likely than from 
other manufacturers. 
One expert clinical advisor indicated support for our conclusions on adverse 
events.  
3.8 Description and critique of evidence synthesis and meta-
analysis carried out by the Company 
Neither the Company, nor the EAC, conducted evidence synthesis/meta-
analysis. 
3.9 Additional work carried out by the External Assessment 
Centre in relation to clinical evidence 
3.9.1 EAC literature search 
The EAC devised their own searches for clinical and economic evidence in 
accordance to the NICE requirements for a Company’s submission of 
evidence. The EAC designed one search for both clinical and economic 
evidence in each of following sources: Medline; Medline In-Process; Embase; 
The Cochrane Library and PubMed. The following additional sources were 
searched for economic evidence:  Cost Effectiveness Analysis registry; 
EconPapers and EconLit. In addition the EAC searched the International 
Clinical Trials Registry Platform and Clinicaltrials.gov for ongoing studies and 
the MHRA for adverse events related to ENDURALIFE-powered CRT-D 
devices. Citation tracking of the Company’s included studies for clinical 
evidence was performed in Web of Science and Scopus and the reference 
lists were checked for other relevant publications. The figure below shows the 
EAC’s study selection process. 
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Figure: EAC study selection flow chart: published studies of CRT-D 
device longevity 
Records identified through 
database searching – duplicates 
removed  
(n =476) 
Additional records identified through other 
sources (supplementary methods) 
(n = 10) 
First screen: title/abstract  
(n = 486) 
 
Records excluded on 
title/abstract  
(n = 465) 
Second screen: assessed for 
eligibility at full text 
(n = 21) 
Full-
text/abstracted  
articles excluded, 
with reasons  
(n = 14) 
(Appendix 2) 
Publications 
included in clinical 
evaluation 
(n = 7 
papers/abstracts 
n = 6 studies) 
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3.10 Conclusions on the clinical evidence 
The Company’s submission of published studies of CRT-D longevity provide 
head-to head comparisons of ENDURALIFE-powered CRT-Ds with 
contemporary comparator CRT-Ds. A minority of these studies have limited 
applicability to the scope by including a large proportion of ICDs as opposed 
to CRT-Ds [6] and also by including devices installed well before the 
introduction of the ENDURALIFE battery technology in the year 2008. 
The longevity studies have the strength that they were conducted in as near 
to normal clinical practice as possible, and in countries that are acceptably 
similar to the UK in terms of population and care pathway. However 
weaknesses include retrospective analysis, and that it is not possible to 
determine why study participants were implanted with a CRT-D from a 
particular manufacturer. 
The published studies of longevity demonstrate that for the period of 
implantation studied since 2008, ENDURALIFE-powered CRT-Ds have better 
longevity than comparator CRT-Ds. 
Some of the CRT-Ds studied in the longevity studies, particularly for 
comparator devices, may no longer be marketed. 
The EAC considers that battery capacity is an important factor which may 
potentially determine CRT-D device longevity, but also that it does not act in 
isolation and that other CRT-D factors are also important (see Technical 
Assessment). It is likely that different manufacturers have each undertaken 
constant CRT-D development focussed on numerous CRT-D components 
such that devices marketed today may have better longevity than their 
predecessors studied in the included published longevity studies. For this 
reason the EAC collected and examined data on predicted battery longevity 
for currently available CRT-Ds across manufacturers. However the EAC 
considers these data to have high uncertainty because they are derived from 
bench testing under conditions which differ across manufacturers. Therefore 
no further analyses were performed by the EAC using projected longevity 
data. 
The EAC accepts the Company’s submission of evidence on the rate of 
complications following replacement procedures for CRT-D. There is a degree 
of duplication whereby data from primary studies included by the company are 
also used in systematic reviews, also within the Company’s submission. For 
this reason the EAC has focussed on systematic review data and other data 
from primary studies that are not duplicated. 
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The EAC observes that adverse events are likely to be frequent, considering 
that CRT-D is a class III implantable medical device, used in people with heart 
failure and potential comorbidities. Consequently the FDA MAUDE database 
records a high number of entries for CRT-Ds. The EAC has seen no evidence 
that ENDURALIFE-powered CRT-Ds present a particular risk of adverse 
events compared to comparator CRT-Ds, and adverse events in normal use 
are not included in the economic evaluation. 
PPRs submitted by the Company demonstrate that, for the vast majority of 
implanted CRT-Ds, it is normal battery depletion that is the reason for CRT-D 
replacement, and not device malfunctions. Otherwise, due to limitations and 
variability across manufacturers in the methods behind PPRs, the EAC 
accepts that the published studies of longevity present more robust data on 
longevity than do the PPRs. 
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4 Economic evidence 
4.1 Published economic evidence 
Critique of the company’s search strategy 
The company’s search was limited to three publically available databases: 
Pubmed, Cochrane and clinical trials.gov, supplemented by additional 
searching of company documentation. The search was limited to English 
language publications. The search did not include all of the databases 
specified in the submission template e.g. Medline, Embase, EconLit and NHS 
EED. The search criteria used are somewhat limited and the EAC conducted 
a more comprehensive search applied to more databases. The company’s 
search was reasonable but could be improved with access to more databases 
and a more thorough strategy. 
Critique of the company’s study selection 
The population used by the company in its selection of economic evidence 
‘patients implanted with CRT-Ds’ differs from the population specified in the 
scope ‘Patients undergoing CRT-D device implantation for heart failure in line 
with NICE Technology Appraisal 314’. The company’s population is broader 
and probably reflects the lack of detail in the published evidence on the 
specific criteria used in TA314. 
Included and excluded studies 
The company included seven studies of which five were published and two full 
papers were academic in confidence. Three of the published studies were 
conference abstracts. The company did not rely on the published studies for 
its model, although the structure of the de novo model is similar to the model 
described in the Gadler draft publication [36]. 
The reason given by the company for excluding three of the studies was 
because of ‘no direct correlation between longevity and costs described’. This 
reason was not part of the company’s exclusion criteria. The EAC has 
obtained these papers and concluded that they are not relevant to the 
economic evaluation. One study was about leads rather than CRT-D devices 
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and the other two papers were not about manufacturer specific devices, but 
CRT-Ds in general. The EAC excluded 3 papers included by the company as 
they were outside the scope.  
The Boriani 2013 paper [37] reports on a model comparing hypothesised 
CRT-D devices with 4 years and 7 years longevity over a 15 year time 
horizon. The devices were not specific named technologies and the 
longevities were not based on data, but were chosen to investigate the impact 
of longevity on costs. Therefore the paper is out of scope as it is not about the 
intervention (ENDURALIFE-powered CRT-Ds). 
The Biffi 2011 paper [38] was about ICD devices and included only 10 
patients with CRT-Ds. It did not include devices from Boston Scientific and is 
therefore outside the scope.  
The Chung 2015 abstract [39] does not directly compare specific devices 
although it includes a device survival curve based on manufacturer data, but 
looks at the costs for different patient groups of using devices with different 
longevity. Therefore the paper is outside the scope. 
Overview of methodologies of all included economic studies 
Two of the abstracts are similar and compared costs for unspecified devices.  
Comparator device longevity was taken from ‘a recent NICE review’ and 
compared with longevity of devices from Boston’s Latitude patient 
management system. One abstract models costs for Australia [40] and the 
other for the UK [41]. The Latitude system is a telemonitoring system and 
longevity data from Latitude may not be directly comparable with data 
reported in the NICE review. The patient populations may be different. Much 
of the Latitude data may originate in the USA. Studies presented as abstracts 
lack sufficient descriptions of their methodology to enable thorough critique.  
Therefore the results from these abstracts should be treated with caution.  
The unpublished Landolina 2016 manuscript [42] describes an economic 
analysis based on a subset of the data from Landolina 2015 [4] with a 6 year 
time horizon and two perspectives: a hospital perspective and the Italian 
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healthcare system perspective. Boston Scientific provided funding for the 
economic analysis. Of 1,726 heart failure patients in Landolina 2015 [4], 1,399 
were included in the economic analysis. The analysis compares recent 
generation devices released from 2007-2010 with older generation devices 
released from 2003-2007 for 3 manufacturers (Boston Scientific, Medtronic 
and St Jude Medical) and for all manufacturers together. Weighted average 
prices of the devices were taken from tender information. The authors found 
that among recent generation CRT-Ds from different manufacturers the total 
cost per patient over 6 years ranged from €25,579 to €31,536 (£21,665 to 
£26,711 XE currency converter €1 = £0.847 on 12/07/2016) with a maximum 
difference in cost of 40% for hospitals and 19% for the Italian healthcare 
system. The authors do not clearly specify which manufacturers supplied the 
least or most costly technologies over the 6 years.  
The unpublished Gadler 2016 manuscript [36] describes XX XXXXXXXX 
XXXXX XXXX X X XXXX XXXX XXXXXXX XXXXX XX XXX XXXX XXXX 
XXXXXXXXX XXXX [X], XXX XXXXXXX XXX XXX XXXXXXXXX XXXXXXXX 
XXX XXXXXXX XXXXXX XXXXXXXXX XXXX. XXXXXXXX XXXX XXX 
XXXXX XXXX XXX (XXXX) [XX]. XXX XXXXXXX XXXXX XX XXX XXXX 
XXXX XXXX XXXXX XXXXXX XXXXXXXXXX XXXXXXX XXXXXXX 
XXXXXXXXXXX XXXXXXXXXX XXX XXXXX XXX XX,XXX (£X,XXX XX 
XXXXXXXX XXXXXXXXX XXX X = £X.XXX XX XX/XX/XX) XXX XXXXXXX 
XXXX 6 XXXXX. XXX XXXXX XXX XXXXXX XX XXXXXX XXXXXXXXXX. 
XXX XXXXXXXXXXX XX XXX XXXXX XXXXXXXX XX XX XXXXXXX XX 
XXX XXXXXXX’X XX XXXX XXXXX XXXXXXXXX XX XXX XXXXXXXXXX. 
Overview and critique of the Company’s critical appraisal for each study 
The company described the economic studies in Table C4 of the 
manufacturer submission and included a quality assessment for each study in 
Table C9, but there was no other critical appraisal of the studies. 
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Does the Company’s review of economic evidence draw conclusions 
from the data available?  
The company noted that all of its selected economic studies were based 
outside of the UK apart from the Duxbury 2014 abstract [41]. Duxbury did not 
report on the cost impact for CRT-D devices separately. Therefore the 
company concluded that a new model was required. 
4.2 De novo cost analysis 
Patients 
The company states that the model population is as described in the scope 
i.e. it is in line with TA314. The clinical data used in the model are taken from 
the Landolina 2016 [42] economic study. This appears to be a sub-set of the 
same population as reported in Landolina 2015 [4].  
Technology 
The technology considered is CRT-D devices using ENDURALIFE battery 
technology, specifically (based on devices used in the Landolina 2015 study 
[4]): 
Table 14 Battery characteristics: Boston Scientific 
Manufacturer 
 
Device Year of CE 
mark 
Battery 
chemistry 
Battery 
capacity 
Boston 
Scientific 
Renewal 2004 Li/SVO 2.00Ah 
Boston 
Scientific 
Livian 2007 Li/CFx-SVO 1.86Ah 
Boston 
Scientific 
Cognis 2008 Li/MnO2 1.84Ah 
 
Our understanding is that Cognis is an ENDURALIFE-powered CRT-D but 
that Livian and Renewal are not. Data in the model was taken from recent 
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generation technologies and this would be from Cognis devices for Boston 
Scientific. 
Comparator(s) 
The economic model includes as comparators the following devices (based 
on devices in the Landolina 2015 study [4]): 
Table 15 Battery characteristics: comparator CRT-Ds 
Manufacturer Device Year of 
CE mark 
Battery 
chemistry 
Battery 
capacity 
Medtronic InSync III 
Marquis 
2003 Li/SVO 0.9Ah 
Medtronic InSync Sentry 2004 Li/SVO 0.89Ah 
Medtronic InSync Maximo 2005 Li/SVO 0.89Ah 
Medtronic  Concerto 2006 Li/SVO 1.00Ah 
Medtronic Consulta 2008 Li/SVO 1.00Ah 
Medtronic Maximo II 2008 Li/SVO 1.00Ah 
Medtronic Protecta 2010 Li/SVO 1.00Ah 
St Jude 
Medical 
Atlas  2003 Li/SVO NR 
St Jude 
Medical 
Epic 2006 Li/SVO NR 
St Jude 
Medical 
Promote 2007 Li/SVO NR 
 
In Landolina 2015 [4] recent generation models were for the most part 
released from 2007 to 2010. 
Model structure 
The model is a decision tree with a 6 year time horizon and an NHS 
perspective. The implant is Boston Scientific (with ENDURALIFE battery 
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technology) as the intervention with comparators from Medtronic or St Jude 
Medical. For each make of implant there is a branch for complications or no 
complications, and for either of these cases there is a branch for death, 
replacement or no replacement at 1 year and at each subsequent year. 
Key assumptions in the model are: 
 The cost of the device is the same as the cost of the comparators. 
 The warranty for the comparators is the same as for Boston Scientific 
devices. 
 Patients attend outpatients 6 monthly for follow-up. 
 Cost of warranty is not explicit in the model and therefore is assumed 
to be included in the cost of the device and equal for all devices. 
 Data from published literature on devices implanted between 2008 and 
2010 can be applied to the latest generation devices currently available 
from the same manufacturers. 
 An estimated percentage improvement in projected battery survival 
was applied to Medtronic technologies to account for the expected 
improvement in the newer generation devices compared with those in 
the published literature. 
The 6 year time horizon of the model is a limitation and raises the question of 
whether a different result would be obtained if the time horizon encompassed 
the patients’ entire lifetime. If we consider the problem from the viewpoint of 
the patient population and consider that most patients would require a device 
replacement during their lifetime, because even the longer lasting devices do 
not outlive most patients, then the question of when the replacement 
happens, before or after 6 years, is less critical. If the number of replacements 
in the patient’s lifetime is equal, then the only difference in cost would arise 
from discounting for costs incurred in the future. In the extremes, the impact of 
device longevity would be important, so a 2 year device lifespan would incur 
multiple replacements and if the lifespan were 20 years there would be no 
need for replacements. The choice of a 6 year time horizon potentially 
exaggerates the cost saving of a slightly longer lasting device. 
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Clinical parameters and variables 
Clinical data in the model is taken from the Landolina 2016 draft manuscript 
[42] for event-free battery survival and Yao et. al. 2007 [21] for cumulative 
probability of patient survival. The incidence of complications is taken from 
Tang et. al. 2010 [20] and the follow-up arrangements from NHS England 
2013/14 NHS Standard Contract for Cardiology: Implantable Cardioverter 
Defibrillator (ICD) and Cardiac Resynchronisation Therapy (CRT) (Adult). 
The EAC scrutinised the Yao paper [20] and found that the data collected 
extends only up to about 2.5 years. Patient survival was modelled statistically 
by the authors up to 6 years and the company has manually extracted 
estimates of cumulative survival probability from the printed graph by eye. 
This is a rather imprecise method and in any case is based upon a model 
rather than actual survival data. Therefore there is some uncertainty regarding 
the values of cumulative probability of survival used in the model. The 
company’s sensitivity analysis explored the probability of survival in a robust 
way and therefore the EAC did not pursue any further analysis. 
The EAC contacted clinical experts to validate the incidence of complications 
used in the model. 
Tele-monitoring 
The model assumes follow up appointments at 6 month intervals with an 
additional post-procedure appointment. There is a trend towards tele-
monitoring in the NHS as this releases Consultant time. There are additional 
items of equipment and software required to facilitate tele-monitoring. In 
addition, the interrogation of the device during tele-monitoring depletes the 
battery to some extent and therefore impacts upon the device longevity. This 
is discussed in more detail in the Technical Report. The model does not 
include tele-monitoring, but assumes all follow-up is conducted during face to 
face visits. The EAC considers the likely impact of including tele-monitoring on 
the per patient costing would be small, although it may have a significant 
impact on hospital services and patient experience. 
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Resource identification, measurement and valuation 
The company has taken procedure costs from the payment by results (PbR) 
tariff and chose not to use NHS reference costs from 2014-15. The tariff is the 
price paid to the organisation for a procedure which may include adjustments 
to support particular policy goals, whereas NHS reference costs reflect the 
actual cost of the procedure averaged across the NHS. Therefore the EAC 
considers that NHS reference costs warrant exploration as a data source for 
the model. 
Table 16 NHS costs 
Model PbR code, 
description 
Model PbR cost NHS reference 
code, 
description 
NHS reference 
cost 
EA56Z 
Implantation of 
Cardiac 
Resynchronization 
Therapy 
Defibrillator (CRT-
D) 
£6201 EY01B 
Implantation of 
cardioverter 
defibrillator with 
cardiac 
resynchronisation 
therapy 
£14,984 
EA12Z 
Implantation of 
Cardioverter; 
Defibrillator only 
£4700 EY10B 
Attention to 
cardiac 
pacemaker or 
cardioverter 
defibrillator 
£2864 
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  EY09B 
Removal of 
cardiac 
pacemaker or 
cardioverter 
defibrillator 
£3709 
Substituting the NHS reference cost for de novo implantation £14,984 and for 
replacement £2,864 gives the results shown in Table 17 below. 
Table 17 Results of model after substituting NHS reference costs 
ENDURALIFE-powered 
CRT-Ds 
£30,957     
Medtronic CRT-Ds £37,087 + £6,131 + 20% 
St Jude Medical CRT-Ds  £35,429 + £4,472 + 14% 
 
Technology and comparators’ costs 
The company based the costs of technologies on the assumption that all of 
the devices cost the same. In the model, the device cost is a key driver and 
therefore this is a significant weakness of the model. A new centralised 
procurement list has been developed to drive out variation and secure better 
prices from suppliers and includes CRT-D. This tends to suggest that prices 
have been variable for these high cost devices. Therefore the EAC considers 
the sensitivity analysis needs to explore differences in the price of the 
technology compared with the comparators, and to identify thresholds at 
which the model becomes cost neutral. 
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Sensitivity analysis 
The company undertook univariate sensitivity analysis. There was no multi-
variate or probabilistic sensitivity analysis.  
4.3 Results of de novo cost analysis 
Table 18 Base-case analysis results 
Technology 
Ave 
cost/patient 
 over 6 years 
Differenc
e 
% 
Difference 
ENDURALIFE-powered CRT-
Ds £22,322     
Medtronic CRT-Ds  £29,158 + £6,836 + 31% 
St Jude Medical CRT-Ds  £27,309 + £4,986 + 22% 
 
Sensitivity analysis results 
The inputs for the sensitivity analysis are shown in Table C21 of the 
manufacturer’s submission. 
Table 19 Difference in cost per patient between Medtronic vs 
ENDURALIFE-powered CRT-Ds (Boston Scientific) 
 
MDT-BSC 
Base Low High 
MDT device costs £6,836 £3,253 £10,420 
MDT event-free battery survival £6,836  £4,623 
Warranty eligibility & uptake £6,836  £4,910 
Cumulative probability of patient 
survival 
£6,836 £5,869  
Replacement procedure cost £6,836 £6,475 £7,197 
Incidence of complications £6,836 £6,573  
Cost of complications £6,836 £6,749 £6,923 
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Table 20 Difference in cost between St Jude Medical vs ENDURALIFE-
powered CRT-Ds (Boston Scientific) 
 
Sensitivity analysis: device survival 
The base case analysis uses empirical data on device longevity from the 
unpublished Landolina (2016) study [42], where CRT-Ds were implanted in 
the interval January 2008-March 2010. In sensitivity analysis the company 
explored the effect of modelling the projected longevity of the latest 
Follow-up costs £6,836 £6,829 £6,844 
Initial procedure cost £6,836 £6,836 £6,836 
Frequency of routine follow-up 
appointments 
£6,836 £6,836 £6,836 
 
STJ-BSC 
Base Low High 
STJ device costs £4,986 £1,649 £8,323 
STJ event-free battery survival £4,986   
Warranty uptake £4,986  £4,400 
Cumulative probability of patient 
survival 
£4,986 £4,179  
Replacement procedure cost £4,986 £4,512 £5,566 
Incidence of complications £4,986 £4,795  
Cost of complications £4,986 £4,872 £5,126 
Follow-up costs £4,986 £4,977 £4,998 
Initial procedure cost £4,986 £4,986 £4,986 
Frequency of routine follow-up 
appointments 
£4,986 £4,986 £4,986 
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generation of CRT-Ds, marketed currently (year 2016). Projected longevity 
was taken from publicly available ‘instructions for use’ documents’. These 
documents provided useable projected longevity data only for Boston 
Scientific and Medtronic devices. The company calculated the average 
percentage improvement in longevity (time) between older devices and the 
contemporary devices (17% for Medtronic devices) and applied this 
percentage improvement to each time point in 0.2 year intervals. For 
Medtronic CRT-Ds, a given percentage of CRT-D survival would be reached 
17% later: in effect, moving the Kaplan-Meier survival curve to the right and 
assuming that here is no change to the shape of the curve. The changes in 
input values to the model were as follows: 
Table 21: modified CRT-D survival rates for company’s sensitivity 
analysis 
 
Year 
Medtronic 
Base case Sensitivity 
analysis 
0 100% 100% 
1 100% 100% 
2 99% 100% 
3 92% 95% 
4 78% 88% 
5 50% 70% 
6 30% 47% 
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Kaplan-Meier analysis of device survival from replacement for battery 
depletion in recent generation devices (marketed post 2007) and with n > 100 
(Landolina, unpublished, 2016 [42]). 
  
The effect of the company’s sensitivity analysis is to reduce the additional cost 
incurred by Medtronic devices over Boston Scientific devices from £6,836 to 
£4,623. 
The EAC acknowledges that this is an attempt to apply the model to the latest 
available CRT-Ds, on a within manufacturer basis (assuming that each 
manufacturer applied the same methods to estimate projected longevity over 
time). However the EAC considers the following as important limitations: 
 The projected longevity data are derived from bench testing and not 
from observed clinical use and are therefore subject to uncertainty.  
 The sensitivity analysis was applied only to Medtronic CRT-Ds in the 
model because St Jude Medical documents do not state projected 
longevity. 
 It is not certain that each manufacturer used the same methods to 
estimate projected longevity over time. 
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 It is unclear if the CRT-D device survival, of newer generation versus 
older generation devices from the same manufacturer, can be 
extrapolated in this way, i.e. that the survival curves shown above [4] 
would retain a similar shape. 
Subgroup analysis 
No sub-group analysis was included. 
Model validation 
The company did not approach clinical advisers to assess the applicability of 
clinical or resource inputs used in the model. They performed internal and 
external quality assurance to ensure the model performs as intended. 
4.4 Interpretation of economic evidence 
The company states that the results of the de novo model are consistent with 
the published economic literature. The two full unpublished papers from 
Gadler 2016 [36] and Landolina 2016 [42] XXXX XXX XXX XXXX XXXX 
XXXX XXXXXXXXX XXXX [X] XXX XXXXX XXXXXX, XXX XXXX XXX X X 
XXXX XXXX XXXXXXX XX XX XX XXXXXXXXXXXX XX XXX XXXXXXX 
XXX XXXXXXX. XXX XXX XXXXXXXXXXX XXXXXXX XXXX XXXX XXXXXX 
XXXXXXXXXXX XX XXXXXXXX XXXXXX XXXX X XXXXX XXXXXXXX, 
XXXXXXXXX XX XXX XXXXXXX’X XX XXXX XXXXX. XXX XXXXXX XXXX 
XXXXX [XX] XXX XXXX XXXXXX XXX XXXXXXX XXXX XXXXXXX XX XXX 
XXXX XXXX XXXXXXXX XXXX XXX XXXXXXX’X XX XXXX XXXXX. Boston 
Scientific provided funding for both of these economic studies. 
Two abstracts [40, 41] demonstrated cost saving for longer lasting batteries 
using data from Boston Scientific’s latitude patient management system when 
compared with unspecified ‘industry standard’ batteries taken from a market 
average from the recent NICE TA 314, based on the NICOR registry which 
includes all implants in the UK for a 10 year period. These studies had longer 
time horizons of 15 years [40] and 10 years [41]. The cost savings of 
switching from industry standard to increased longevity batteries in Priest 
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2015 [40] were, in Australian dollars, $9,313 (£5,318 1 AUD = £0.571, XE 
currency converter 15/07/16) per patient over 15 years. The results in 
Duxbury 2014 [41] were expressed as additional procedures that could be 
funded from the reduction in replacements. Both studies were co-authored by 
Boston Scientific. 
The company has correctly identified the main limitation of the model, being 
the difference in device models in the published literature compared to those 
available now.  They also note that the sample size at year 6 is small. The 
company investigated the effect of a price difference between the technology 
and the comparators by applying +/- 20% to the average selling price (based 
on all manufacturers in NICE TA314) for Medtronic CRT-Ds and for St Jude 
Medical CRT-Ds. The effects of these analyses on the model are small 
compared to the effects of using highest and lowest device list prices: 
purchase cost is a key driver of the model. 
4.5 Additional work undertaken by the External Assessment 
Centre in relation to economic evidence 
The EAC obtained list prices for currently available CRT-D devices and ran 
the model with list prices in place of the average selling price. 
List price analysis 
The EAC obtained list price data from manufacturers and used these as 
model inputs. 
Table 22 Manufacturer list prices 
Make Model List price 
Boston Scientific XXXXXX/XXXXXXX £XX,XXX XX £XX,XXX 
St Jude Medical XXXXXX XXXXXX XXX £XX,XXX 
XXXXXX XXXXXX £XX,XXX 
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XXXXX XXXXXX £XX,XXX 
Medtronic XXXX £XX,XXX 
XXXXX £XX,XXX 
XXXX XXXX £XX,XXX 
XXXXX XXXX £XX,XXX 
XXXXXX £XX,XXX 
XXXXXX £XX,XXX 
XXXXXX £XX,XXX 
XXXXXX XXXX £XX,XXX 
XXXXXX XXXX £XX,XXX 
XXXXXX XXXX £XX,XXX 
XXXXXXXX XXX XXXXXX XXXX XX XXX XXXXX XX XXX XXXXXX XXXX 
XXXXX XXX XXXX XX XXX XXXXX XXXXXXXXXXXXX XXXXX XXX 
XXXXXX XXXXX XX XXXXX XX. XX XXXX XXXX XXXXXXXXXX-XXXXXXX 
XXX-XX XXXXXX XXXX XXXXXX XXXX XXXXXXXXX, XXX XXXXXX XXXX 
XXXXXX XXXXXXXX XXXX XX XXXX. 
XXXXX XX XXXXXXX XX XXXXX XXXX XXXXX XXXXXX XXXX XXXXX 
XXX XXXXXXX XXXXXX XXXX XXXX XXXXXXXXXXXX 
XXXXXXXXXX-
XXXXXXX XXX-
XX 
£XX,XXX   
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XXXXXXXXX £XXXXX -£XXX -X% 
XX XXXX £XXXXX +£XXXXX +XX% 
XXXXXXXX XXX XXXXXX XXXX XX XXX XXXXX XX XXX XXXXXXX XXXX 
XXXXX XXXX XXXX XX XXX XXXXXXXXXXXXX XXXXX XXX XXXXXXX XX 
XXXXX XX. XXXXXXXXXX-XXXXXXX XXX-XX XXX XXXX XXXXXXXXX 
XXXXXXXX XXXX XXXXXXXXX XXX-XX, XXX XXXXXX XXXX XXXXXX 
XXXXXXXX XXXX XX XXXX XXX-XX. 
XXXXX XX XXXXXXX XX XXXXX XXXXX XXXXXXX XXXX XXXXX XXX 
XXXXXXX XXXXXX XXXX XXXX XXXXXXXXXXXX 
XXXXXXXXXX-
XXXXXXX XXX-
XX 
£XX,XXX   
XXXXXXXXX 
XXX-XX 
£XX,XXX -£X,XXX -X% 
XX XXXX 
XXXXXXX XXX-
XX 
£XX,XXX +£X,XXX +X% 
The company has provided evidence that list prices do not reflect actual 
selling prices. This evidence is average selling prices collated by Eucomed 
based on quarterly sales data: each manufacturer receives both a generalised 
market average selling price plus their own specific average selling price. The 
EAC accepts that differences between list price and actual selling price exist.  
However the assumption in the model that all of the device prices are the 
same (based on the generalised average selling price) is also unrealistic. The 
company explored varying the generic average selling price by +/- 20% for 
Medtronic CRT-Ds and for St Jude Medical CRT-Ds. Because device cost 
was identified as a key driver of the model, the EAC undertook threshold 
analysis as follows. 
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Threshold analysis of price difference between devices 
The EAC investigated the effect of allowing a price difference between the 
devices and calculated the threshold at which the technology becomes cost 
saving compared with the comparators. 
Table 25: Threshold implant costs 
 Boston 
scientific 
Medtronic St Jude Medical 
CRT-D implant 
cost 
£12,404 £7,546 £8,546 
CRT-D 
replacement 
cost 
£11,858 £7,000 £8,000 
Table 26 Model results using threshold cost values 
ENDURALIFE-
powered CRT-
Ds 
£22,322   
Medtronic CRT-
Ds 
£22,042 -£281 -1% 
St Jude Medical 
CRT-Ds 
£22,058 -£264 -1% 
If the cost of implanting the CRT-D and replacing the CRT-D is left as in the 
base case for ENDURALIFE-powered CRT-D devices, the technology 
becomes cost-incurring when the Medtronic implant cost is £7,546 and the St 
Jude implant cost is £8,546 with all other model inputs unchanged. Therefore 
accepting all else in the model ENDURALIFE-powered CRT-Ds remain cost 
saving until they are £4,858 more expensive to purchase than Medtronic 
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CRT-Ds and £3,858 more expensive to purchase than St Jude Medical CRT-
Ds.  
Analysis using manufacturer warranty data 
The EAC obtained data on the warranty period for currently available models 
of the comparator and used these values in the model. In the model, the 
company assumes that the warranty arrangements for the comparator 
technologies are the same as those for Boston Scientific i.e. full replacement 
cost up to 4 years and an additional 2 year pro rata warranty credit. In the 
base case it is assumed that warranty refunds are not claimed. In sensitivity 
analysis the option for 100% of refunds to be eligible and claimed within the 
warranty period is explored. 
The EAC has obtained information on actual warranties for Medtronic and St 
Jude devices from the manufacturers and these are listed in Tables 27 and 28 
below.  
A clinical expert stated to the EAC that CRT-D warranties are comprehensive 
because CRT-D devices are robust, and that in reality warranties are very 
rarely claimed by clinical teams as process to do so in most hospitals are 
lacking. 
Table 27 Warranty information supplied by St Jude Medical 
XXXXXX XXXXX XXXXXX/ 
XXXXXXXXXX 
XXXXXXXX 
XXXXXX XXXXXX XXX XXXX – XXX 
XXXXXXXXXX XX 
XXXXXX XXXXXX 
X XXXXX XX XXXXXXXX 
XXXXXX XXXXXX XXXX – XXX 
XXXXXXXXXX XX 
XXXXXX XXXXXX 
X XXXXX XX XXXXXXXX 
  84 of 115 
External Assessment Centre report: ENDURALIFE-powered CRT-D devices for the treatment 
of heart failure 
Date: July 2016 
XXXXX XXXXXX XXXX - XXX 
XXXXXXXXXX XX 
XXXXX XXXXXX 
X XXXXX XX XXXXXXXX 
Table 28 Warranty information supplied by Medtronic 
XXXXXX XXXXX XXXXXX/ 
XXXXXXXXXX 
XXXXXXXX 
 XXXXXXXX 
 XXXXXXXX XX 
 XXXXXX XX 
XXXX-XX X XXXXX XXXX + X 
XXXXX XXX-XXXX 
 XXXXXXXX 
 XXXXXXXX XX 
XXXX-XXXX X XXXXX XXXX + X 
XXXXX XXX-XXXX 
 XXXX 
 XXXXX 
XXXX X XXXXX XXXX + X 
XXXXX XXX-XXXX 
 XXXX XXXX 
 XXXXX XXXX 
XXXX XXXX: X XXXXX XXXX 
+ X XXXXX XXX-XXXX 
XXXXX: X XXXXX 
XXXX + X XXXXX XXX-
XXXX 
 XXXXXX 
 XXXXXX 
 XXXXXX 
 XXXXXX XXXX 
 XXXXXX XXXX 
 XXXXXX XXXX 
XXXX XXXXXX, XXXXXX & 
XXXXXX, XXXXXX 
XXXX: X XXXXX XXXX 
+ X XXXXX XXX-XXXX 
XXXXXX XXXX, 
XXXXXX XXXX: X 
XXXXX XXXX + X 
XXXXX XXX-XXXX 
 
XXX XXX XXX XXXXXXXXXXX XXX XXXXXX XXXXXXXX XXXXXXXXXXX 
XXXXXXXX XX XXX XXXXXXXXXXXXX XXXX XXX XXXXX XX XXXXXXXX 
XXX XXXXXXXX XXXXXXXX. XXX XXXXXXXXX XXX XX XXXX XX XXXX X 
XXXX X XXXX XXXXXXXX, XXXXX XXXXXXX XX XXX XX XXXX XXX-X 
XXXXXX XXX XX XXXX XXXX, XXXXX XXXX, XXXXXX, XXXXXX, XXXXXX 
XXXX, XXXXXX XXXX XXXX XXXXXXXXX. XXX XXXXXXXX XXX 
XXXXXXXXXX-XXXXXXX XXX-XX XXX XXXX XXXXXXXXX. XXX XXX 
XXXXXXXXX XXXXXX XXX XXXXXXXX XXXXXX XXXXXXX XXXXXX X 
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XXXXX, XXX XXX XXXXX XXXX XXXXXXX XXXXX XX X XXXXX, XX XXX 
XXXXXXXXXX X XXXXX XXXX XXX XXXX XXXXXXXX XXXXX XXX XX 
XXXXXXXX. XX XXX XXXXX XX XXX XXX XXXXX ‘XXXXXXXXXX XX 
XXXXXXXXXX XXXXXXX’ XX XXX%. The results are given in Table 29. 
 
Table 29 Results using warranty information from manufacturers 
ENDURALIFE-
powered CRT-
Ds 
£22,322   
Medtronic CRT-
Ds 
£23,644 +£2,279 +11% 
St Jude Medical 
CRT-Ds 
£23,027 +£1,663 +8% 
 
Complications 
The company’s rates of different kinds of complications used in the model 
were taken from a randomised study comparing de novo ICD versus de novo 
CRT-D in people with heart failure, and were the same rates as used by NICE 
in their technology appraisal 314. Complications were reported for the 30 day 
period following de novo implantation of CRT-D devices [20] . Rates of 
complications used as inputs to the model were infection: 2.4%, lead 
dislodgment or haematoma requiring re-intervention: 8.5%, and device-pocket 
problem requiring revision: 0.5%, with rates assumed to be equal for de novo 
and replacement procedures. The EAC considered that rates of complications 
may differ between de novo implant and replacement procedures. The EAC 
consulted clinical experts, one of whom highlighted that the best available 
data on complications following replacement of cardiac implantable electronic 
devices (CIEDs) comes from a cohort study conducted in Denmark [9]. This 
study reported complications following 4335 de novo implantations and 1136 
replacement procedures for CIEDs: the data are not disaggregated for 
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different types of CIED, but the EAC considers that this is a lesser limitation 
than assuming that de novo and replacement procedures have equal rates of 
complications. 
Clinical experts also reported their experience of complications to the EAC as 
follows: 
Clinical expert 1 
 de novo implants have complication rates 8-10% with an infection rate 
of 0.6-1% 
 Replacements have similar complication rates but higher infection rate 
(2-2.5%) 
 Infections are likely under-reported, can lead to complicated extractions 
and require implantation of a new CRT-D and leads on the 
contralateral side. 
Clinical expert 2 
 Frequently quoted rates of infection are around 2% 
 The rate of complications requiring re-intervention (lead dislodgement, 
haematoma) of 8.5% is much higher than would be expected at box-
change. Haematoma requiring re-intervention should be <0.5% and 
lead displacement should be <1%. 
 The rate of device pocket problem requiring revision of 0.5% is lower 
than conventionally quoted and is inconsistent with the infection point 
as infection is a sub-set of pocket problems requiring re-intervention. 
The EAC considered that the company’s sensitivity analysis covered the 
majority of the discussion above and also the range of different complications 
reported in the cohort study [9]. An exception is that the cohort study found 
the rate of infection in new implants to be 0.6% (24/4355). The EAC inputted 
this rate of infections for new implants in the model: the effect is very small as 
shown in Table 30: the effect on the model is negligible: a 1% percentage 
increase in excess cost for St Jude Medical CRT-Ds. 
Table 30 Effect of changing the rate of infection (new implants) from 
2.4% to 0.6% 
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XXXXXXXXXXXX Total cost 
Excess cost 
over BSC 
% excess cost 
over BSC 
XXXXXXXXXX-
XXXXXXX XXX-
XX £22,322     
XXXXXXXXX 
XXX-XX £29,158 + £6,836 +XX% 
XX XXXX 
XXXXXXX XXX-
XX £27,309 + £4,986 +XX% 
The EAC conclusion on rates of complications used in the model is that they 
are broadly appropriate, with variations adequately explored in sensitivity 
analysis. 
Analysis using manufacturer projected longevity 
The EAC hoped to develop some scenarios based upon the projected battery 
lifespan as estimated by the manufacturers or from PPR reports for currently 
available models of the technology and comparators. However the EAC 
concluded this was not a valid approach because: 
Bench test data: 
 Settings may not reflect clinical realities 
 Different manufacturers choose to report different settings, and 
therefore results are not comparable 
 Single figure given for longevity, rather than a graph of survival against 
time 
PPR data: 
 Data is usually collected passively, resulting in under-reporting of 
malfunctions 
 Assumption that devices are still functioning unless they are returned, 
or the manufacturer notified 
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 Data can only show device survival for the length of time that the 
device has been implanted 
 Patients and settings may be different for different devices, this may be 
a systematic difference due to different device capabilities or functions. 
 By the time a complete longevity curve is available the device is likely 
to have been superseded. 
The model uses a year by year survival curve to represent device longevity 
based on data from Landolina 2016 [42]. Manufacturer’s projected longevity is 
a point estimate.  Calculating projected device longevity is complex and there 
is no agreed standard approach. Each manufacturer makes its own 
assumptions in its calculation. Therefore the estimates of projected longevity 
are not directly comparable from a technical viewpoint, and incorporating the 
data into the model would require further assumptions regarding the survival 
curve. The longevity data used in the model are taken from published papers 
on devices implanted in 2008-10 and many are no longer on the market. 
Increases in projected longevity by manufacturers, and longer warranties tend 
to suggest manufacturers have confidence that newer devices will last longer 
but this remains to be proven. More information on the calculation of projected 
longevity is available in the Technical Report. 
4.6 Conclusions on the economic evidence 
The company has made the most of the available data in constructing the 
model. The company’s model is based upon observational data which shows 
that ENDURALIFE-powered CRT-Ds had increased longevity compared to 
devices from St Jude Medical and Medtronic in 2008-10. Whether the 
increased longevity delivered a cost saving depends on the purchase cost of 
the devices. The base case shows that if the devices all have the same 
purchase cost of £12,404, then ENDURALIFE-powered CRT-Ds in 2008-10 
were cost saving. Using list prices supplied by the manufacturers 
ENDURALIFE-powered CRT-Ds were not cost saving compared with 
Medtronic CRT-Ds. 
The main weakness of the model and published data is that it appears to 
relate to devices no longer on the market due to the rapid turnover of new 
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models of the technology. For example the Medtronic models listed in the 
Landolina 2016 draft manuscript [42] as ‘recent generation’ are the Consulta 
(withdrawn 2015), the Maximo II (withdrawn 2016) and the Protecta 
(withdrawn 2016). XXX XX XXXX XXXXXXX XXX XXXXX XXXXXX XX 
XXXXXX XXXXXXXXXX XX XXXXXXX, XXXXXXX XX XXXX’X XXXXXXX 
XXXXXX XXXXXX XX XX XXXXXX XXXXXX XXX, XXXXXX XXXXXX XXX 
XXXXX XXXXXX. XXXXXXXXX XXX XXXXXX XXXXXXXXXX XXX XXXXXX 
XXXXXXXXXX XXXXX XX XXX XXXXXXXXXX XX XXXXXX, XXXXXXX 
XXXXXXX XXXXXX XXX XXXXXXX, XXXXXXX, XXXXXXX XXX XXXXXX. 
XXXXXXX XXXXXX XXXX XXXXXX XXXXXXXXXX XXX XXXXX XXXXXXX 
XX XXXXXXXXXX XXXXXXX XXXXXXXXXX. As device longevity is related 
to other factors as well as battery technology, past performance is not 
necessarily indicative of future results.  
There have been technology developments other than battery technology that 
can be expected to impact on device longevity, for example quadripolar 
devices and improvements to device algorithms. Typically an innovation is 
developed by one manufacturer and then something similar is adopted by the 
other players within a short time. These technologies are rapidly evolving in a 
highly competitive market, and this poses challenges for research and 
evidence based medicine. By the time evidence is produced the devices may 
be no longer on the market.  
Whilst we have comparative data from clinical studies, these are 
retrospective, observational studies with a risk of bias. 
Some key drivers of the model are based upon assumptions. For example the 
cost of the technology is assumed to be equal to the cost of comparators. The 
warranty arrangements are also assumed to be the same for all 
manufacturers. 
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Impact on the cost difference between the technology and comparator 
of additional clinical and economic analyses undertaken by the External 
Assessment Centre 
The EAC has explored device purchase cost in two ways. Firstly we have 
used list prices for current technologies supplied by manufacturers. This 
changes the result of the model from ENDURALIFE-powered CRT-Ds being 
cost saving, to the point where other manufacturer’s devices are less costly, 
all else being unchanged. Secondly, we used the average selling price for 
ENDURALIFE-powered CRT-Ds and then allowed the comparator technology 
prices to fall until the point at which each became cost saving. There is 
considerable difference between the list prices and the overall average selling 
price, and it is possible that average selling price per manufacturer is less 
variable than the list prices. This remains unknown whereas list prices are 
known. 
The EAC has looked at actual warranties based on information supplied by 
the manufacturers and found that longer warranties offered by the comparator 
manufacturers reduce the cost saving of the technology but did not change 
the result from cost saving, all else being unchanged and assuming 100% of 
warranties are claimed. Where the warranty extends beyond 6 years, this 
could not be included in the model due to the 6 year time horizon.  
The EAC extended the company’s sensitivity analysis for complications based 
on information from clinical experts, but this had a minimal effect on the 
results. 
5 Conclusions 
Boston Scientific has submitted the best available evidence and the EAC 
does not have significant concerns about its quality and robustness. The EAC 
is concerned about the applicability of the evidence to decision-makers today 
and this weakness was highlighted by the company.  
Whether differences in longevity between ENDURALIFE-powered CRT-Ds 
and comparators lead to a reduction in replacement procedures depends on 
patient life expectancy. 
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We have identified an additional concern regarding the purchase price used in 
the model. Using the list prices from the manufacturers changes the result of 
the model from ENDURALIFE-powered CRT-Ds being cost saving to cost-
incurring. 
Remaining uncertainties are the longevity of devices currently on the market, 
patient life expectancy, and the accuracy and comparability of manufacturer 
predicted device longevity from bench tests. 
 
6 Implications for research 
Evidence on ENDURALIFE battery technology incorporated in older 
technologies is available and shows that ENDURALIFE powered CRT-Ds had 
better longevity at that time. There is a lack of evidence on the longevity of 
devices that are powered by ENDURALIFE battery technology and that are 
currently on the market, and for current competitor devices. While we feel that 
the ENDURALIFE-powered CRT-Ds have likely continued to be developed, 
we consider that this is possible also for comparator CRT-Ds, and this does 
not have to be based on the battery technology in isolation. By the time 
evidence on current technologies is captured it is likely that the technologies 
will have developed further. Capturing data on a patient register would allow 
retrospective evaluation of technologies, but would not assist with decision-
making now. Long term clinical outcomes can only be determined in a long 
term study. Predictive longevity is based on manufacturer bench testing. 
Bench testing would be more useful if the testing methods used and settings 
for reporting the predicted longevity were consistent across manufacturers. 
More detail is available in the technical report. 
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Appendix 1 Ongoing studies identified by the EAC 
The EAC identified three ongoing studies, none of which are directly relevant 
to the decision problem. These are as follows. 
Boston Scientific is sponsoring the CAPTIVATE study, an evaluation of the 
safety of automatic threshold algorithms used in the AUTOGEN CRT-D. The 
primary outcome measure is the system-related complication rate at three 
months. The study is due to complete in June 2017. 
Boston Scientific sponsors the ENABLE MRI study (Expanding MRI Access 
for Patients With New and Existing ICDs and CRT-Ds). The study’s objective 
is to collect data to confirm the safety and effectiveness of the ImageReady™ 
MR Conditional Defibrillation System when used in the 1.5T MRI environment 
under the labelled Conditions of Use. The primary outcome measure is the 
MR scan-related System Complication Free Rate. The study is due to 
complete in December 2019.  
Guidant Corporation sponsors the RallyX4 study (Maximizing CRT Delivery by 
Using MultipolAr Coronary Sinus Lead FamiLy ACUITY® X4). The objective 
of this study is to collect clinical data on safety and performance of ACUITY 
X4® leads when used in a standard clinical setting. The primary outcome 
measure is the Phrenic Nerve Complication Free Rate. The estimated 
completion date is December 2016. 
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Appendix 2 studies of longevity not included 
Details of 14 studies comparing CRT-D longevity across manufacturers considered by the EAC but judged to be not relevant to the 
scope 
Record Paper / 
abstract 
Implant 
period 
Explant 
period 
Devices 
studied: ICD, 
CRT-D, other, 
mixed 
Follow-up n 
(ENDURALIFE-
powered 
CRT-Ds) 
Reported 
longevity by 
manufacturer 
Applicability 
to Scope 
Accept as 
additional 
evidence? 
Biffi [22] Abstract Not 
reported 
Mar 2013-
Nov 2014 
715 ICDs 
including 366 
CRT-Ds 
Median 
longevity 
1728 days 
for CRT-D 
devices 
(4.7 years) 
Not known 5-year survival 
(CRT-D): 
MDT 26% 
BSC 74% 
SJM 50% 
BTK 28% 
 
Low. 
Estimated 
implant 
period c2008-
2009 
No 
Gakenhe
imer [23] 
Paper Not 
reported 
Jan 2007- 
Jan 2011 
801 explanted 
ICDs 
Not 
reported 
Not known Reported 
graphically 
only. BSC 
devices had 
best longevity. 
Low. 
Estimated 
implant 
period c2003-
2007 
No 
Hauser 
2010 [24] 
Abstract Not 
reported 
2000-2010 2541 ICDs 
including 428 
CRT-Ds. 
Not 
reported 
Not known No difference 
between 
manufacturers 
found for 
CRT-Ds 
Low.  
Estimated 
implant 
period pre-
2008 
No 
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Record Paper / 
abstract 
Implant 
period 
Explant 
period 
Devices 
studied: ICD, 
CRT-D, other, 
mixed 
Follow-up n 
(ENDURALIFE-
powered 
CRT-Ds) 
Reported 
longevity by 
manufacturer 
Applicability 
to Scope 
Accept as 
additional 
evidence? 
Hauser 
2014 [25] 
Abstract Not 
reported 
2010-2013 1556 Mixed 
ICD PG & 
CRT-D. 
Proportions not 
reported. 
 
% 
ENDURALIFE-
powered CRT-
D not known. 
Total 100 
months 
(median / 
mean not 
reported) 
Not known Not quantified 
precisely. BSC 
had greatest 
longevity, 
followed by 
MDT, followed 
by SJM 
(p<0.001) 
Low.  
Estimated 
implant 
period c2006-
2010 
No 
Horlbeck 
[26] 
Paper Jun 1988-
Jun 2009 
- - - None - None. No 
ENDURALIF
E-powered 
devices 
studied 
(paper names 
devices 
studied). 
No 
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Record Paper / 
abstract 
Implant 
period 
Explant 
period 
Devices 
studied: ICD, 
CRT-D, other, 
mixed 
Follow-up n 
(ENDURALIFE-
powered 
CRT-Ds) 
Reported 
longevity by 
manufacturer 
Applicability 
to Scope 
Accept as 
additional 
evidence? 
Johanse
n [27] 
Abstract 2007-2013 Not 
reported 
2793 CRT-Ds: 
MDT 651 
BTK 369 
BSC 136 
SJM 1587 
Not 
reported 
Not known Battery 
depletion/devic
e failure rates: 
MDT 43 
(6.7%) 
BTK 4 (1.1%) 
BSC 1 (0.7%) 
SJM 33 
(2.1%). 
 
4 year survival: 
MDT 81.1% 
BTK 95.8% 
BSC 95.7% 
SJM 93.6% 
 
Battery 
depletion was 
the reason for 
88% of device 
replacements 
 
Limited. No 
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Record Paper / 
abstract 
Implant 
period 
Explant 
period 
Devices 
studied: ICD, 
CRT-D, other, 
mixed 
Follow-up n 
(ENDURALIFE-
powered 
CRT-Ds) 
Reported 
longevity by 
manufacturer 
Applicability 
to Scope 
Accept as 
additional 
evidence? 
Knops 
[28] 
Paper Oct 1998-
Dec 2006 
- - - None - None. 
Implant 
period 
precedes 
2008. 
No 
ENDURALIF
E-powered 
devices 
studied 
(paper names 
devices 
studied). 
No 
Manyam 
[29] 
Abstract 2002-2012 Not 
reported 
1338 patients 
with CRT-D: 
SJM 304 
BSC 279 
MDT 755 
Median/me
an not 
reported.  
Not known Rate of CRT-
Ds reaching 
ERI within 4 
years: 
SJM 17% 
BSC 24% 
MDT 39% 
 
Projected 
longevity 
overestimated 
survival in SJM 
and BSC 
devices, but 
MDT 
projections 
were accurate. 
Low: implant 
period 
includes a 
long pre-2008 
interval. 
No 
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Record Paper / 
abstract 
Implant 
period 
Explant 
period 
Devices 
studied: ICD, 
CRT-D, other, 
mixed 
Follow-up n 
(ENDURALIFE-
powered 
CRT-Ds) 
Reported 
longevity by 
manufacturer 
Applicability 
to Scope 
Accept as 
additional 
evidence? 
Parisi 
[30] 
Abstract Not known Mar 2013-
Nov 2014 
366 patients 
with CRT-Ds 
replaced for 
battery 
depletion only: 
MDT 164 
BSC 135 
SJM 60 
BTK 7  
Median/me
an not 
reported 
Not known 5 year survival 
rate: 
MDT 26% 
BSC 74% 
SJM 50% 
BTK 28% 
LV output was 
a predictor of 
early depletion 
(HR 1.44, 95% 
CI 1.28-1.63, 
p<0.0001). 
BSC was a 
protective 
factor (HR 
0.35, 95% CI 
0.28-0.44, 
p<0.0001). 
Estimated 
implant 
period 2008-
2009 
No 
Salgado 
[31] 
Abstract Jan 1995 – 
Dec 2012 
Not 
reported 
21 patients 
with CRT-Ds: 
BSC/Guidant 
15 
MDT 1 
SJM 5 
Median/me
an not 
reported: 
data imply 
follow-up 
to 
replaceme
nt 
Not known Mean (SD) 
longevity, 
years: 
BSC/Guidant 
4.52 (0.96) 
MDT 4.17 (no 
SD) 
SJM 4.62 
(1.25) 
Low. Few 
CRT-Ds 
studied. 
Estimated 
implant 
period 1991-
2008 
No 
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Record Paper / 
abstract 
Implant 
period 
Explant 
period 
Devices 
studied: ICD, 
CRT-D, other, 
mixed 
Follow-up n 
(ENDURALIFE-
powered 
CRT-Ds) 
Reported 
longevity by 
manufacturer 
Applicability 
to Scope 
Accept as 
additional 
evidence? 
Seegers 
[32] 
Paper 1998-2010 Not 
reported 
1665 devices 
including 593 
CRT-Ds 
Median/me
an not 
reported. 
Total = 10 
years 
3 (COGNIS) Median 
generator 
lifetime (95% 
CI): 
MDT 5.7 years 
(5.5, 5.9) 
BSC/Guidant 
5.4 (5.0,5.4) 
BTK 5.2 
(5.0,5.4) 
Low. 3 
ENDURALIF
E-powered 
CRT-Ds 
studied 
No 
Thijssen 
[33] 
Paper 1996-2011 Not 
reported 
4673 devices 
including 1853 
CRT-Ds: 
BIO 194 (11%) 
BSC/Guidant 
1005 (54%) 
MDT 634 
(34%) 
SJM/Ventritex 
20 (1%) 
Mean 4.1 
(SD 3.2) 
years 
Not known Mean battery 
longevity 
(years): 
BIO 4.7 (SD 
0.1) 
BSC/Guidant 
5.3 (SD 0.1) 
MDT 5.8 (SD 
0.2) 
SJM/Ventritex 
5.0 (0.2) 
Low: implant 
period 
includes a 
long pre-2008 
interval. 
No 
Zanon 
2015 [34] 
Abstract Not 
reported 
Mar 2013 
– Nov 
2014 
715 ICDs 
including 366 
CRT-Ds: 
MDT 164 
BSC 135 
SJM 60 
BTK 7 
Mean/medi
an not 
reported 
Not known 5 year survival: 
MDT 26% 
BSC 74% 
SJM 50% 
BTK 28% 
Limited: 
estimated 
implant 
period c2008-
2009 
No 
  99 of 115 
External Assessment Centre report: ENDURALIFE-powered CRT-D devices for the treatment of heart failure 
Date: July 2016 
Record Paper / 
abstract 
Implant 
period 
Explant 
period 
Devices 
studied: ICD, 
CRT-D, other, 
mixed 
Follow-up n 
(ENDURALIFE-
powered 
CRT-Ds) 
Reported 
longevity by 
manufacturer 
Applicability 
to Scope 
Accept as 
additional 
evidence? 
Zanon 
2016 [35] 
Extensio
n of 
study 
above by 
same 
team 
Abstract Not 
reported 
Mar 2013 
– May 
2015 
953 patients 
with ICDs 
Mean/medi
an not 
reported 
Not known BSC showed 
the longest 
CRT-D 
longevity. 
Median service 
life (all CRT-D 
manufacturers) 
4.9 (IQR 
4.0,5.7) years. 
Limited: 
estimated 
implant 
period c2008-
2010 
No 
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Appendix 3 Critical Appraisal checklists for longevity studies published as full 
journal articles 
 
Study identification 
Alam 2014 , Alam 2016 
Guideline topic: Review question no: 
Checklist completed by:  AC 
 Circle or highlight one option for each question: 
A. Selection bias (systematic differences between the comparison groups) 
A1  The method of allocation to 
treatment groups was unrelated to 
potential confounding factors (that 
is, the reason for participant 
allocation to treatment groups is not 
expected to affect the outcome[s] 
under study) 
Yes No Unclear Retrospective study. It is not known why 
patients received any particular CRT-D 
device. 
A2  Attempts were made within the 
design or analysis to balance the 
comparison groups for potential 
confounders 
Yes No Unclear The paper reports differences in potential 
confounders across comparison groups 
A3  The groups were comparable at 
baseline, including all major 
confounding and prognostic factors 
Yes No Unclear Baseline characteristics were 
comparable between patients with 
devices from different manufacturers, 
except for differences consisting of 
higher rates of coronary artery disease 
(P = 0.037) and higher serum creatinine 
levels (P = 0.047) for patients in the 
Boston Scientific group (P = 0.037), and 
lower rates of hypertension for patients in 
the Medtronic group (P = 
0.031). 
Based on your answers to the above, in your opinion was selection bias present? If so, what is the likely direction of 
its effect? 
Low risk of bias Unclear/unknown risk High risk of bias 
Likely direction of effect: not known. 
B. Performance bias (systematic differences between groups in the care provided, apart from the 
intervention under investigation) 
B1  The comparison groups received 
the same care apart from the 
intervention(s) studied 
Yes No Unclear N/A 
B2  Participants receiving care were 
kept 'blind' to treatment allocation 
Yes No Unclear N/A 
B3  Individuals administering care were 
kept 'blind' to treatment allocation 
Yes No Unclear N/A 
Based on your answers to the above, in your opinion was performance bias present? If so, what is the likely 
direction of its effect? Paper does not report this detail. 
Low risk of bias Unclear/unknown risk High risk of bias 
Likely direction of effect: not known. 
C. Attrition bias (systematic differences between the comparison groups with respect to loss of 
participants) 
C1  All groups were followed up for an 
equal length of time (or analysis 
was adjusted to allow for 
Yes No Unclear Of the 746 patients implanted with CRT-
ICDs at the hospitals of the University of 
Pittsburgh Medical Center, 94 were 
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differences in length of follow-up) excluded from the analysis because they 
were lost to follow-up within a month 
after device implantation, because they 
chose to follow-up in a device clinic 
closer to their place of residence. Device 
manufacturers of excluded patients were 
Boston scientific (n = 32), Medtronic (n = 
55), and St Jude medical (n = 7) and 
were in equivalent proportions to the 
overall cohort. Six patients implanted 
with CRT-ICDs from Biotronik were 
excluded from the analysis because of 
the small number of devices from this 
manufacturer that precludes meaningful 
comparison. 
 
In 2016 further losses to follow-up (n = 
25) appear to be entirely in the Medtronic 
group. 
C2  a. How many participants did not complete treatment in each group? 
 
b. The groups were 
comparable for treatment 
completion (that is, there 
were no important or 
systematic differences 
between groups in terms of 
those who did not 
complete treatment) 
Yes No Unclear Paper does not show how many patients 
were censored due to competing risks. 
C3  a. For how many participants in each group were no outcome data available? 
b. The groups were comparable 
with respect to the availability of 
outcome data (that is, there were no 
important or systematic differences 
between groups in terms of those 
for whom outcome data were not 
available) 
Yes No Unclear N/A 
Based on your answers to the above, in your opinion was attrition bias present? If so, what is the likely direction of 
its effect? 
Low risk of bias Unclear/unknown risk High risk of bias 
Likely direction of effect: not known. 
D. Detection bias (bias in how outcomes are ascertained, diagnosed or verified) 
D1  The study had an 
appropriate length of 
follow-up 
Yes No Unclear N/A 
D2  The study used a precise 
definition of outcome 
Yes No Unclear Data suggest that all devices reaching ERI 
were replaced due to battery depletion 
D3  A valid and reliable method 
was used to determine the 
outcome 
Yes No Unclear N/A 
D4  Investigators were kept 
'blind' to participants' 
exposure to the 
intervention 
Yes No Unclear N/A 
D5  Investigators were kept Yes No Unclear N/A 
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'blind' to other important 
confounding and 
prognostic factors 
Based on your answers to the above, in your opinion was detection bias present? If so, what is the likely direction 
of its effect? 
Low risk of bias Unclear/unknown risk High risk of bias 
Likely direction of effect: not known. 
 
  
  103 of 115 
External Assessment Centre report: ENDURALIFE-powered CRT-D devices for the treatment of heart failure 
Date: July 2016 
Study identification 
Ellis 2016  
Guideline topic: Review question no: 
Checklist completed by:   
 Circle or highlight one option for each question: 
A. Selection bias (systematic differences between the comparison groups) 
A1  The method of allocation to treatment 
groups was unrelated to potential 
confounding factors (that is, the reason for 
participant allocation to treatment groups is 
not expected to affect the outcome[s] under 
study) 
Yes No Unclear Retrospective study. It is not 
known why patients received any 
particular CRT-D device. 
A2  Attempts were made within the design or 
analysis to balance the comparison groups 
for potential confounders 
Yes No Unclear The paper reports differences in 
potential confounders across 
comparison groups 
A3  The groups were comparable at baseline, 
including all major confounding and 
prognostic factors 
Yes No Unclear Minor differences observed by 
manufacturer in NYHA class, 
whether 100% pacemaker 
dependent, and preimplant 
LVEF. Many more patients were 
male, which reflects patient 
population. 
Based on your answers to the above, in your opinion was selection bias present? If so, what is the likely direction of 
its effect? 
Low risk of bias Unclear/unknown risk High risk of bias 
Likely direction of effect: not known 
. 
. 
. 
. 
B. Performance bias (systematic differences between groups in the care provided, apart from the 
intervention under investigation) 
B1  The comparison groups received the same 
care apart from the intervention(s) studied 
Yes No Unclear N/A 
B2  Participants receiving care were kept 'blind' 
to treatment allocation 
Yes No Unclear N/A 
B3  Individuals administering care were kept 
'blind' to treatment allocation 
Yes No Unclear N/A 
Based on your answers to the above, in your opinion was performance bias present? If so, what is the likely 
direction of its effect? 
Low risk of bias Unclear/unknown risk High risk of bias 
Likely direction of effect: 
. 
. 
. 
. 
C. Attrition bias (systematic differences between the comparison groups with respect to loss of 
participants) 
C1  All groups were followed up for an equal 
length of time (or analysis was adjusted to 
allow for differences in length of follow-up) 
Yes No Unclear N/A 
C2  a. How many participants did not complete treatment in each group? 
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b. The groups were comparable 
for treatment completion (that is, 
there were no important or 
systematic differences between 
groups in terms of those who did 
not complete treatment) 
Yes No Unclear Not reported, though paper presents 
all competing risk events. 
C3  a. For how many participants in each group were no outcome data available? 
b. The groups were comparable with 
respect to the availability of outcome data 
(that is, there were no important or 
systematic differences between groups in 
terms of those for whom outcome data 
were not available) 
Yes No Unclear Exclusions not reported. No 
obviously missing data. 
Based on your answers to the above, in your opinion was attrition bias present? If so, what is the likely direction of 
its effect? 
Low risk of bias Unclear/unknown risk High risk of bias 
Likely direction of effect: not known 
. 
. 
. 
. 
D. Detection bias (bias in how outcomes are ascertained, diagnosed or verified) 
D1  The study had an appropriate 
length of follow-up 
Yes No Unclear  
D2  The study used a precise 
definition of outcome 
Yes No Unclear N/A 
D3  A valid and reliable method was 
used to determine the outcome 
Yes No Unclear N/A 
D4  Investigators were kept 'blind' to 
participants' exposure to the 
intervention 
Yes No Unclear N/A 
D5  Investigators were kept 'blind' to 
other important confounding and 
prognostic factors 
Yes No Unclear N/A 
Based on your answers to the above, in your opinion was detection bias present? If so, what is the likely direction 
of its effect? 
Low risk of bias Unclear/unknown risk High risk of bias 
Likely direction of effect: 
. 
. 
. 
. 
 
  
  105 of 115 
External Assessment Centre report: ENDURALIFE-powered CRT-D devices for the treatment of heart failure 
Date: July 2016 
 
Study identification 
Landolina 2015 
Guideline topic: Review question no: 
Checklist completed by:  AC 
 Circle or highlight one option for each question: 
A. Selection bias (systematic differences between the comparison groups) 
A1  The method of allocation to treatment 
groups was unrelated to potential 
confounding factors (that is, the reason for 
participant allocation to treatment groups is 
not expected to affect the outcome[s] 
under study) 
Yes No Unclear Retrospective study. It is not 
known why patients received any 
particular CRT-D device. 
A2  Attempts were made within the design or 
analysis to balance the comparison groups 
for potential confounders 
Yes No Unclear The paper reports differences 
across comparison groups in 
device parameters only, not 
patient demographic/morbidity 
factors 
 
Paper makes use of multivariate 
analysis to overcome confounding 
A3  The groups were comparable at baseline, 
including all major confounding and 
prognostic factors 
Yes No Unclear No patient factors are reported 
Based on your answers to the above, in your opinion was selection bias present? If so, what is the likely direction of 
its effect? 
Low risk of bias Unclear/unknown risk High risk of bias 
Likely direction of effect: not known. 
B. Performance bias (systematic differences between groups in the care provided, apart from the 
intervention under investigation) 
B1  The comparison groups received the same 
care apart from the intervention(s) studied 
Yes No Unclear N/A 
B2  Participants receiving care were kept 'blind' 
to treatment allocation 
Yes No Unclear N/A 
B3  Individuals administering care were kept 
'blind' to treatment allocation 
Yes No Unclear N/A 
Based on your answers to the above, in your opinion was performance bias present? If so, what is the likely 
direction of its effect? Paper does not report this detail. 
Low risk of bias Unclear/unknown risk High risk of bias 
Likely direction of effect: not known. 
C. Attrition bias (systematic differences between the comparison groups with respect to loss of 
participants) 
C1  All groups were followed up for an equal 
length of time (or analysis was adjusted to 
allow for differences in length of follow-up) 
Yes No Unclear No substantial differences in 
follow-up. Reporting of this by 
group is very clear. 
C2  a. How many participants did not complete treatment in each group? 
 
b. The groups were comparable 
for treatment completion (that is, 
there were no important or 
systematic differences between 
groups in terms of those who did 
Yes No Unclear Paper reports how many patients were 
censored due to competing risks. 
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not complete treatment) 
C3  a. For how many participants in each group were no outcome data available? 
b. The groups were comparable with 
respect to the availability of outcome data 
(that is, there were no important or 
systematic differences between groups in 
terms of those for whom outcome data 
were not available) 
Yes No Unclear N/A 
Based on your answers to the above, in your opinion was attrition bias present? If so, what is the likely direction of 
its effect? 
Low risk of bias Unclear/unknown risk High risk of bias 
Likely direction of effect: not known. 
D. Detection bias (bias in how outcomes are ascertained, diagnosed or verified) 
D1  The study had an appropriate 
length of follow-up 
Yes No Unclear N/A 
D2  The study used a precise 
definition of outcome 
Yes No Unclear  
D3  A valid and reliable method was 
used to determine the outcome 
Yes No Unclear N/A 
D4  Investigators were kept 'blind' to 
participants' exposure to the 
intervention 
Yes No Unclear N/A 
D5  Investigators were kept 'blind' to 
other important confounding and 
prognostic factors 
Yes No Unclear N/A 
Based on your answers to the above, in your opinion was detection bias present? If so, what is the likely direction 
of its effect? 
Low risk of bias Unclear/unknown risk High risk of bias 
Likely direction of effect: not known. 
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Study identification 
von Gunten 2015 
Guideline topic: Review question no: 
Checklist completed by:  AC 
 Circle or highlight one option for each question: 
A. Selection bias (systematic differences between the comparison groups) 
A1  The method of allocation to treatment groups 
was unrelated to potential confounding 
factors (that is, the reason for participant 
allocation to treatment groups is not 
expected to affect the outcome[s] under 
study) 
Yes No Unclear Retrospective study. It is not 
known why patients received 
any particular CRT-D device. 
 
The paper reports on ICDs for 
out of scope patient indications 
including VVIs and DDDs in 
addition to CRT-D. 
A2  Attempts were made within the design or 
analysis to balance the comparison groups 
for potential confounders 
Yes No Unclear The paper reports baseline 
characteristics (demographic, 
cardiac morbidity, NYHA class, 
medical therapies) for the entire 
cohort and not by analysis 
groups. 
A3  The groups were comparable at baseline, 
including all major confounding and 
prognostic factors 
Yes No Unclear See above 
Based on your answers to the above, in your opinion was selection bias present? If so, what is the likely direction of 
its effect? 
Low risk of bias Unclear/unknown risk High risk of bias 
Likely direction of effect: not known. 
B. Performance bias (systematic differences between groups in the care provided, apart from the 
intervention under investigation) 
B1  The comparison groups received the same 
care apart from the intervention(s) studied 
Yes No Unclear N/A 
B2  Participants receiving care were kept 'blind' 
to treatment allocation 
Yes No Unclear N/A 
B3  Individuals administering care were kept 
'blind' to treatment allocation 
Yes No Unclear N/A 
Based on your answers to the above, in your opinion was performance bias present? If so, what is the likely 
direction of its effect? Paper does not report this detail. 
Low risk of bias Unclear/unknown risk High risk of bias 
Likely direction of effect: not known. 
C. Attrition bias (systematic differences between the comparison groups with respect to loss of 
participants) 
C1  All groups were followed up for an equal 
length of time (or analysis was adjusted to 
allow for differences in length of follow-up) 
Yes No Unclear 154 patients in total were lost to 
follow-up; 189 transferred to 
other hospitals; and in either 
case were censored. This is not 
reported for different analysis 
groups. 
C2  a. How many participants did not complete treatment in each group? 
 
b. The groups were comparable 
for treatment completion (that is, 
there were no important or 
systematic differences between 
Yes No Unclear Paper reports how many patients 
were censored due to competing 
risks: 
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groups in terms of those who did 
not complete treatment) 
822 died 
85 underwent heart transplant 
189 moved to other hospitals 
154 were lost to follow-up 
These are not reported by analysis 
groups 
 
C3  a. For how many participants in each group were no outcome data available? 
b. The groups were comparable with respect 
to the availability of outcome data (that is, 
there were no important or systematic 
differences between groups in terms of those 
for whom outcome data were not available) 
Yes No Unclear Not reported by analysis groups 
Based on your answers to the above, in your opinion was attrition bias present? If so, what is the likely direction of 
its effect? 
Low risk of bias Unclear/unknown risk High risk of bias 
Likely direction of effect: not known. 
D. Detection bias (bias in how outcomes are ascertained, diagnosed or verified) 
D1  The study had an appropriate 
length of follow-up 
Yes No Unclear N/A 
D2  The study used a precise 
definition of outcome 
Yes No Unclear  
D3  A valid and reliable method was 
used to determine the outcome 
Yes No Unclear N/A 
D4  Investigators were kept 'blind' to 
participants' exposure to the 
intervention 
Yes No Unclear N/A 
D5  Investigators were kept 'blind' to 
other important confounding and 
prognostic factors 
Yes No Unclear Unlikely 
Based on your answers to the above, in your opinion was detection bias present? If so, what is the likely direction 
of its effect? 
Low risk of bias Unclear/unknown risk High risk of bias 
Likely direction of effect: not known. 
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Appendix 4: Cohort study checklist 
 
Specialist Unit for Review Evidence (SURE) 
Questions to assist with the critical appraisal of cohort studies1  
This work is licensed under the Creative Commons Attribution - Non Commercial-ShareAlike 3.0 Unported License. To view a copy 
of this license visit http://creativecommons.org/licenses/by-nc-sa/3.0/  
Citation:  Kirkfeldt (2014) 
Are there other companion papers from the same study? 
 Yes/ Can't tell/ No 
1. Is the study design clearly stated? Yes 
2. Does the study address a clearly focused 
question? 
Consider:  Population; Exposure (defined and accurately 
measured?); Comparator/Control; Outcomes. 
Yes 
Population: People receiving CIED 
treatment 
Exposure: CIED treatment 
Comparator: no control. However, 
comparisons were made based on 
device type and whether the device was 
implanted de novo, replaced the 
generator or carried out an upgrade/lead 
revision. 
Outcomes: total number of 
complications, major complications, 
minor complications, mortality.  
3. Are the setting, locations and relevant dates 
provided? 
Consider: recruitment period; exposure; follow-up & data 
collection. 
The setting, location and relevant dates 
are provided.  
The study was carried out across all 14 
centres that carry out CIED procedures 
in Denmark from May 2010 to April 
2011. The study included a 6 month 
follow-up in order to capture cumulative 
complications.  
4. Were participants fairly selected? 
Consider: eligibility criteria; sources & selection of 
participants; method of follow-up; for matched studies – 
details of matching criteria and number of exposed or 
unexposed. 
The only inclusion criterion was that the 
patient had undergone CIED treatment. 
All Danish patients who underwent CIED 
replacement were included; however, 
patients with epicardial systems were 
excluded. Therefore, participant 
selection appears to be fair as all 
patients who underwent CIED treatment 
were included. 
5. Are participant characteristics provided? 
Consider if: sufficient details; a baseline table is 
included. 
A table on patient and procedure 
characteristics is included. The table is 
quite comprehensive with age, gender, 
BMI and centre volume. Procedure 
characteristics include CIED type, 
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procedure type, operator volume and 
procedure priority.  
6. Are the measures of exposures & outcomes 
appropriate?  
Consider if the methods of assessment are valid & 
reliable. 
The outcomes reported are the 
complications noted during the study 
and so are appropriate. The authors 
have also included mortality as an 
outcome. 
7. Was bias considered? e.g. recall or selection 
bias 
Bias was not considered. However, 
selection bias would not have been an 
issue due to the authors including every 
patient that underwent CIED treatment 
during May 2010 to April 2011.  
8. Is there a description of how the study size 
was arrived at? 
The study included all patients that 
underwent CIED treatment in Denmark 
from May 2010 to April 2011. The 
authors explained that patients who 
received treatment with epicardial 
systems were excluded.  
9. Are the statistical methods well described? 
Consider: How missing data was handled; were 
potential sources of bias (confounding factors) 
controlled for; How loss to follow-up was addressed. 
The statistical methods are well 
described. Between group analyses, in 
addition to how binary regression was 
carried out, are described.   
10. Is information provided on participant flow?  
Consider if following provided: flow diagram; numbers of 
participants at each stage; details of drop-outs; details of 
missing participant data; follow-up time summarised; 
numbers of outcome events. 
There is no information on participant 
flow. As this was a retrospective study 
using patient charts the authors were 
able to present all information.  
11. Are the results well described? 
Consider if: effect sizes, confidence intervals/standard 
deviations provided; the conclusions are the same in the 
abstract and the full text. 
The results are well described with 95% 
confidence intervals given in addition to 
p values where required.  
12. Is any sponsorship/conflict of interest 
reported? 
The study was supported with research 
grants from Biotronik and Medtronic. 
Some of the authors have received 
speaker fees from Biotronik, Boston-
Scientific and Biosense Webster. 
13. Finally…Did the authors identify any limitations 
and, if so, are they captured above? 
The authors state the following 
limitations: 
 Only complications documented on 
patient charts were identified. 
 Data on drug regimens undertaken 
by the patients was not collected and 
so could confound the results. 
 The study was not randomised and 
so confounding factors may not be 
controlled for. 
 6 month complications are deemed to 
be short-term complications and not 
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long-term. The authors state that 
longer follow-up is important for 
CIED-related infections. 
This checklist should be cited as: Specialist Unit for Review Evidence (SURE) 2016. Questions to assist with the critical appraisal of 
cohort studies. Available at: http://www.cardiff.ac.uk/insrv/libraries/sure/checklists.html 
1
 Devised with reference to the STROBE consideration and elaboration article: Vandenbroucke JP, von Elm 
E, Altman DG, Gøtzsche PC, Mulrow CD, et al. (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): 
Explanation and Elaboration. PLoS Med 4(10): e297. doi:10.1371/journal.pmed.0040297 
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